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Abstract 
 
The University of Manchester 
Phillip Robert Law 
Doctor of Philosophy 
Tissue Engineering of the Human Atrium – Approaching Mechanisms of Genesis and 
Control of Atrial Fibrillation 
1st September 2010 
 
Cardiovascular disease is prevalent across the western world and is a major cause of 
morbidity and mortality, accounting for approximately a third of all fatalities. Investigating 
the heart by simulating its electrophysiology via the aid of mathematical models has 
advanced significantly over the past 60 years and is now a well established field. While 
much of the research focus is placed on the ventricles, the study of the atria is in 
comparison neglected. Therefore this Thesis is focused on the genesis and maintenance of 
atrial fibrillation (AF). A series of case studies are performed whereby established 
biophysically detailed mathematical models are implemented and modified to incorporate 
electrophysical alterations of atrial cells resulting from a variety of external conditions. 
 
The opening section of this Thesis is dedicated to developing a background to the field, 
including a discussion into the clinical aspect of the diagnosis and management of AF. The 
suitability of two atrial cell models is discussed and the development of single cell, 1D, 
2D, and 3D multi-scale simulation protocols are described in detail. In addition 
measurements taken to quantify the arrhythmogenic properties of the cells susceptibility to 
AF are outlined. The second section is focused on the incorporation of conditions thought 
to enhance atrial tissues ability to initiate and maintain the genesis of AF. Included is a 
case study into the missence S140G gene mutation, and elevated physiological levels of the 
hormone Homocystein. The third section investigates the effectiveness of well established 
and widely used pharmacological treatments such as Beta-Blockers. In addition possible 
avenues of investigations for the development of atrial specific drugs are explored. These 
include blocking of the ultra rapid potassium channel and a more novel target for therapy 
via the targeting of 5HT4 receptors; which is transcribed solely in the atria and alters the 
electrophysical properties of the L-type Calcium current. The final part of this Thesis is 
dedicated to the development of a 2D atrial sheet model which includes electrical and 
spatial heterogeneities via the inclusion of multiple cell types and basic fiber orientation 
respectively. This allows for an investigation into the role that heterogeneities play in role 
genesis and maintenance of AF. 
 
The main finding of this Thesis is that alterations to the electrophysiology of atrial cells, 
due to external factors, can be successfully simulated via the implementation of 
mathematically detailed atrial cell models. It is concluded that simulations of the KENQ1 
mutation and elevated levels of Homocystein successfully reproduce conditions which 
increase the onset of AF. Established treatments such as Beta-Blockers are found to have 
limited effectiveness. Possible theoretical treatments, such as the blocking of IKur, are found 
to provide a small amount of therapeutic benefit. In contrast, investigations into the effects 
of Serotonin were inconclusive. The study into the 2D atria indicated the importance that 
heterogeneities play in atria. The conclusions show that models provide a powerful tool 
when investigating how changes to electrophysiology of cells are manifested at a multi-
scale level. The models also have their limitations and require further advancement to 
improve their accuracy. 
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Chapter 1 
 
Introduction 
 
Cardiac disease and its effect on underlying electrophysiology have been studied since the 
birth of modern medicine. However, the mechanisms which underpin the disease are still 
poorly understood, this provides a testament to the complex and multi-faceted nature of the 
condition. This thesis is primarily focused on the study of atrial fibrillation (AF), which is 
characterised by rapid uncoordinated contractions of the atrial myocardium. While AF is 
not in itself life threatening the paroxysmal nature of the condition and subsequent 
continual re-admittance of patients to hospital poses a considerable financial and time 
consuming burden to health care budgets (Boriani, Diemberger et al. 2004). The study of 
AF in the clinical setting is often costly and raises many ethical questions. The 
development of mathematical models which can simulate the onset of AF computationally 
provides a complimentary method by which the condition can be examined ethically and in 
a cost effective manner. In this introductory chapter I aim to give an overview of the 
clinical problem, a brief description of diagnosis techniques and current treatment 
methodology. In addition I have outlined current techniques for modifying atrial cell 
models and methods for quantifying the arrhythmogenic effects of these changes. 
1.1 Why cardiac disease is a cause for concern 
 
Cardiac disease in a major cause of morbidity and mortality across the western world 
contributing to approximately a third of all fatalities in the UK and US (Whiteley 2007). 
Recent evidence suggests cardiac disease is also a burgeoning problem in emerging 
economies such as China (Zhang 2009). Due to the paroxysmal nature of AF and 
associated long term treatment strategies there is a substantial burden on health care 
budgets in the UK and elsewhere around the world. Traditionally, cardiac disease was the 
reserve of the old (Aronow 2009; Wetzel, Hindricks et al. 2009). However, due to current 
lifestyle choices there is an increasing prevalence of the condition in an ever younger 
population dynamic.  Therefore study into the genesis and maintenance of AF is crucial to 
developing new and cost effective strategies for treatment. In addition increased 
understanding of the underlying causes of AF allows preventative measures to be explored. 
1.2 The anatomical structure of the heart  
The human heart, which can be seen in Figure 1.1 weighs approximately between 250 and 
300 grams. It located in the centre of your mediastinum and is contained in a membranous 
 18 
sac called the pericardium, which protects the heart and anchors it in its surrounding. The 
heart is comprised of four chambers, two superior atria and two inferior ventricles. The 
atria function is to receive blood and pump it into the ventricles where there is a greater 
mechanical force to expel the blood to the rest of the body. The left ventricle and left atria 
(LA) combined is referred to as the left heart, and is responsible for pumping blood round 
the systemic circuit. The right atria (RA) and right ventricle is referred to as the right heart, 
and it pumps blood round the pulmonary circuit. Due to the increased force required to 
provide the power blood through the systemic circuit the left ventricle is larger in volume 
than the right. Back flow is potentially harmful (Trichon, Felker et al. 2003) and is 
prevented by a series of four valves, the tricuspid and mitral valves, which are located 
between the atria and ventricle in the right and left heart respectively, and the pulmonary 
and aortic valves which are located on the entrance on the opening of the aorta and the 
pulmonary artery (Gray 1918).  
 
1.3 The electrophysiology of a heartbeat 
A heartbeat begins with an initiation of an excitation wave from a specialised group of 
cells in the right atrium collectively known as the sinoatrial (SA) node (Chen, Joung et al. 
2009). The node is located in the superior lateral wall of the RA near the opening of the 
superior vena-cava (Gray 1918). These cells spontaneously depolarise at regular intervals, 
thus the SA-node acts as the hearts pacemaker. Once the cells depolarise the resultant 
electrical wave travels through the RA and then on to the LA causing them to beat in rapid 
succession. After the wave transverses the atrium it enters the atrioventricular (AV) node at 
which point the speed of propagation is reduced due to a combination of cell diameter (2-
3µm) and complex intracellular circuitry.  The slowing of the wave is of significance as it 
allows the ventricles to beat approximately 1/10
th
 of a second after the atrium, allowing 
time for the blood to be pushed into the ventricle before its beat.  Once the wave has 
passed the AV node it is rapidly transmitted through the bundle of His along the left and 
right bundle branches and through the Purkinje network.  This network is comprised of 
specialized cells in which conduction velocity is increased significantly.  The rapid 
velocity of the wave along the Purkinje fibres allows the action potential be to be 
distributed throughout the entire ventricular wall to ensure simultaneous contraction; one 
full heartbeat typically takes approximately one second. AF occurs when the normal 
conduction pathway of the electrical wave is disrupted. Dependant on how the conduction 
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pathway is altered directly effects how AF in manifested in the patient. This explains why 
patients with AF show a range in the severity of their symptoms. When a patient initially 
develops AF the symptoms are relatively minor. However, untreated the condition 
increases in severity over time. 
 
1.4 The action potential of a cardiac myocyte and wave propagation 
 
The tissue of the myocardium is constructed from multiple cell types. However, the cell 
which provides the mechanical force required for a heartbeat is the cardiac myocyte (Yin, 
Zhang et al. 2005). It is the combined mechanical force of these cells contracting in a 
coordinated manner which provides the power required to pump the interstitial fluid 
around the body.  A typical resting potential (RP) of an atrial cell is approximately -80 mV, 
where the net charge entering and exiting the cell across the cell membrane remains 
negligible. (Courtemanche, Ramirez et al. 1998; Nygren, Fiset et al. 1998). Cardiac 
myocytes are arranged in strands with each cell connected to its neighbour via gap 
junctions. As a neighbouring myocyte depolarises ions pass into the cell resulting in 
elevated membrane potential. If membrane potential is elevated sufficiently the ion-
channel responsible for the rapid flow of sodium ions into the cell will open causing 
membrane potential to become positive. At such elevated potentials multiple ion-channels 
become active which control the flow of potassium and calcium ions across the cell 
membrane. The flow of these ions across the cell membrane alters the potential of the cell 
over time and is observed as an action potential (AP); a typical example of which is shown 
in Figure 1.2. It is during an AP that a myocyte will contract. The topography of the AP is 
created as different ion-channels and pumps transport the various ions across the cell 
membrane. The shape of an AP can provide an insight into individual ion-channel 
behaviour. Gap junction coupling between adjacent myocytes provides a mechanism that 
allows the cells to contract sequentially in quick progression. This creates an excitation 
wave which propagates around the structure of the heart, resulting in a successful 
heartbeat.  
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Figure 1.1 Anatomical structure of the mammalian heart with  points of interest indicated which 
include the atria, ventricles, tricuspid and bicuspid valves, aorta, and inferior vena cava (Gray 
1918). 
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Figure 1.2 Schematic of the human AP simulated using the Courtemanche et al model with major 
inward (↑)and outward (↓) currents responsible for the depolarization and repolarisation of the 
atrial myocytes indicated. 
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1.5 The clinical problem 
 
The aim of computational cardiology is to develop understanding of cardiac physiology 
with the ultimate aim of improving current clinical treatment techniques and aid 
pharmacological development. Therefore this section of the introduction provides a 
background into the history of AF along with current clinical methodology behind 
diagnosis and treatment options available. 
 
1.5.1 Historical perspective 
The first recoded case of AF was identified in the yellow emperor’s classic of  internal 
medicine (Huang 1949) which was written in approximately 2000 BC, where an irregular 
pulse was associated with a poor prognosis for the patient. However, the first document 
case of AF described as ‘fibrillation of the auricles’ was identified in 1628 by William 
Harvey (Harvey and Lederle Laboratories. 1987). Although AF had been observed there 
was no reliable way of identifying a patient with AF. Before a treatment could be 
considered an accurate diagnosis method was required. The invention of the stethoscope in 
18
th
 century provides some aid to the clinician it was not until the early 1900’s with the 
invention of the ECG that an accurate method for the diagnosis of AF was devised. ECGs 
remain the clinicians’ primary apparatus for diagnosis to this day.  The ECG provided an 
accurate method for the diagnosis of AF. However, treatment of AF still provided an 
obstacle for clinicians.  While there had been anecdotal evidence that the properties of the 
digitalis leaf (Digitalis purures) brought some relief to patients with sever heart failure the 
mechanism by which application of the leaf help relieve the symptoms was unknown, it 
was in fact first pharmacological intervention treatment method discovered. 
Even as recently as a few decades ago the treatment options for AF were limited.  The 
standard treatment recommended for a patient identified to be in an AF episode was to 
perform a cardioversion, either pharmacologically via administration of either Quinidine, 
or via DC shock. Patients in permanent AF were prescribed digitalis as a rate control 
treatment method (CK Friedberg 1966; P Wood 1968). The treatment of AF has improved 
significantly in recent years, both in management and prevention of AF. There is now a 
wide array of treatment options available to the clinician to achieve the best outcome for 
the patient. These include anti-coagulation drugs, surgical interventions, and a range of rate 
and rhythm control drugs (Van Wagoner 2007). 
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1.5.2 Associated risk factors for AF 
 
The increased incidence of AF has long been associated with an ageing population. 
However, a detailed analysis of the risk factors associated with the condition were not fully 
studied until 1948 in the Framingham study (Dawber, Moore et al. 1957). This longitudinal 
study focused on the town of Framingham in Massachusetts, USA. The aim was to 
quantify the risk factors for the onset of AF in a large sample of population over an 
extended period of time, the study is now on its third generation. Over the past fifty years 
the study had identified numerous risk factors including smoking, hypertension, diabetes, 
high blood cholesterol, and obesity (Kannel and McGee 1979; Castelli, Garrison et al. 
1986; Kannel, Cupples et al. 1991; Gillman, Kannel et al. 1993). While the study had 
provided insight into how lifestyle choices increase the risk of AF it did not focus on other 
biologically inherent mechanisms which result in the genesis of AF. More recent clinical 
studies have showed how genetic defects, hormone imbalances, and AF induced electrical 
remodelling (AFER) can facilitate the genesis of AF (Kharche, Garratt et al. 2008; Knight 
2009; Law, Kharche et al. 2009). 
 
1.6 The genesis of AF 
 
AF is self perpetuating in nature and has multiple contributing factors. The schematic in 
Figure 1.3 outlines the hypothesis that “AF begets AF” and shows how remodelling of the 
atria occurs both electrically and structurally. Typically electrical remodelling occurs on 
relatively short time period. In contrast, structural remodelling tends to occurs over an 
extended period of time. Initiation of a patient’s first AF episode is likely to begin due to 
an ectopic beat, which may be the result of underlying etiology. If the atrial tissue is 
healthy, exhibiting normal AP duration (APD) and therefore normal atrial effective 
refractory period (ERP) any re-entrant waves born as a result of the ectopic beats are 
broken up and normal sinus rhythm (SR) is resumed; this is known as paroxysmal AF. 
Such episodes may be short and the patient may be unaware that this has occurred. 
However, the underlying mechanism which resulted in the ectopic beat remains. Therefore, 
AF is likely to reoccur. If these episodes reoccur at regular enough intervals then the 
initiation of re-entry is likely to increase in frequency and lengthen in period. This is due to 
AFER which results from prolonged periods of rapid pacing causing remodelling of the 
major ionic currents. As a consequence the myocyte exhibits a permanently reduced APD 
and ERP (Wijffels, Kirchhof et al. 1995). Reduced ERP shortens the wavelength at which 
atrial tissue can sustain re-entry, resulting in an increased susceptibility to AF genesis. 
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Structurally, prolonged periods of rapid pacing result in a decrease in contractibility of the 
atrial myocytes thereby decreasing the ability of the atria to expel blood, this would 
possibly cause thrombosi to be formed. These place the patient at increased risk of strokes 
or cause a myocardial infarction. In addition rapid pacing results in hypertrophy due to 
increases in the atrial myocytes size, alterations to the extracellular matrix in terms of 
increased fibroblast density, and chamber dilation due to hypertrophy. Increased atrial size 
allows greater substrates for re-entrant waves to be sustained before being terminated. 
 
1.7 Current clinical methods for diagnosis of AF 
 
The invention of the ECG provided clinicians with a reliable tool for the detection of 
abnormalities in the electrophysiology of the heart and is still the mainstay of the diagnosis 
procedure. However, for an ECG to be an accurate diagnosis tool it requires a skilled 
clinician. Modern advances in computing have allowed for the clinician diagnosis skills to 
be augmented, providing more accurate and powerful diagnoses tool (Slocum, Sahakian et 
al. 1992) . However, due to the complex multi-faceted nature of the genesis of AF it is vital 
to know the underlying mechanism through which AF is born to implement the most 
effective treatment. There is still no single technique for identifying the underlying 
etiology for the onset of AF. Therefore, the diagnosis of AF remains one of exclusion 
resulting from a careful evaluation, including thorough collection of medical history, 
physical examination, blood pressure measurement, laboratory tests, ECG, and possibly, 
chest x-ray and exercise testing (Kozlowski, Budrejko et al. 2009).  
 
1.8 Clinical treatment of AF 
 
Clinical treatment of AF is dependant on progression and the underlying etiology. In 
Figure 1.3 which shows how “AF begets AF” numbered entries indicate the various 
treatment options available and when they should be implemented to be of most effect. For 
a patient initially admitted to hospital who is identified to be suffering from an AF episode 
the standard method for restoring SR is to apply a cardioversion, thereby resetting the 
electrical activity in the myocardium so that normal SR be resumed (Reiffel 2009). This in 
normally achieved by pharmacological methods or by a direct DC shock to the torso. 
However, cardioversion provides only a short them solution as the underlying mechanism 
which resulted in the genesis of the arrhythmia is still present. If normal SR can be restored 
with a cardioversion then the patient is referred to as being in persistent AF, if the patient 
reverts back into AF soon after a cardioversion that patient is know to be in permanent AF.  
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Patients diagnosed with AF are at risk of blood clots, which place the patient at increased 
risk of stroke. Therefore it is standard to provide the patient with a anticoagulants 
(Sobieraj-Teague, O'Donnell et al. 2009). The long term options for the management of AF 
are aimed at maintaining normal SR; these are referred to as rhythm control strategies. The 
treatment strategy which a clinician chooses in outlined in the NICE guidelines and a 
representative flow chart is shown in Figure 1.4. The success of these treatments are 
limited and in trials it had been concluded that anti-arrhythmic drugs administered after 
cardioversion still result in 70-85 % of patients developing further complications with in a 
year (Lafuente-Lafuente, Mouly et al. 2006) (Segal, McNamara et al. 2000; Olshansky, 
Rosenfeld et al. 2004). Surgical intervention can also be implemented in rhythm control 
strategies and had been found to be a successful treatment option (Levy 2006). AF may be 
initiated via an ectopic beat origination from auto-rhythmic cells located in the pulmonary 
vein (Haissaguerre, Jais et al. 1998). Surgical intervention aimed at ablating this region to 
remove the focal point of any ectopic beat may provide a possible ‘cure’ for the condition. 
If rhythm control options are deemed no longer possible the patient may be moved to a rate 
control strategy. In rate control the contraction of the ventricles is managed either by 
pharmacological means, or surgically via the ablation of the AV node and replacement by 
a biventricular pacemaker. This allows for precise control of the rate of ventricular 
contractions (Abraham, Fisher et al. 2002; Bode and Schutte 2009). The addition of mini-
defibrillators to the artificial pacemaker allow for the immediate cardioversion of the heart, 
limiting the risk of possible stroke from the AF episode. 
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Figure 1.3 Schematic showing the mechanisms for AF and targets for possible therapeutic 
treatments. Electrical remodeling (left side) typically occurs on short time scales and structural 
remodeling (right side) occurs over longer periods. The initiation AF due to an ectopic beat results 
in rapid pacing of the atrial cells allowing AFER to occur.  The shortening of APD and atrial ERP 
increase the tissues susceptibility to AF being initiated. Structural remodeling occurs as rapid 
pacing results causing hypertrophy and LA dilation, increasing the myocardial volume and 
therefore increasing the tissues susceptibility to re-entry.  Possible treatments options and are 
numbered and indicate present and future treatment interventions, these include β-Blockers, 
antiarrhythmic drugs (AADs), pulmonary vein isolation, gap junction and sodium channel 
modulators, maze surgery, anti-inflammatory drugs (AIDs), rennin-angiontensin-aldosterone 
system (RAAS). 
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Figure 1.4 Diagram showing NICE treatment guidelines for management of AF via rate or rhythm 
control. Treatment is chosen depending on the categorisation of AF. Paroxysmal AF: short periods 
of re-entry until the atria returns to SR independent of intervention. Persistent AF: AF occurs until 
cardioversion is performed. Permanent AF: Atria return to AF shortly after a cardioversion is 
performed. 
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1.9 The role of computer simulation and mathematical modelling 
 
Multiple risk factors and several roots to the initiation of AF combined with the self 
perpetuating nature of the condition means the diagnosis and treatment of AF remains a 
challenge. Understanding the mechanisms underpinning the genesis and maintenance of 
AF are vital to developing successful clinical diagnosis and treatment techniques. While 
the conditions behind AF are complex the treatment options available remain simple in 
design as can be seen in Figure 1.4, when compared to Figure 1.3, which provides a 
glimpse into the overall complexity of the condition. Traditionally clinicians have opted 
for a multi-treatment approach relying on their experience to determine which options are 
best for the patient. Such treatment methodology while effective may lead to unnecessary 
treatments being prescribed, with implications to the patient in terms of side effects, and an 
increased treatment cost. Current scientific methods for studying AF are split between 
clinical trials, research on cellular electrophysiology, and more recently computer 
simulation. These research methods have provided key information that has led to a much 
more profound understanding of the arrhythmogenesis and cardiac physiology in general. 
The role of computer modelling in particular provides a powerful tool for the study of 
cardiac electrophysiology due to its relatively inexpensive setup costs and limited ethical 
considerations required for its application. Biophysically detailed mathematical models 
allow for results recorded from single cell wet lab experiments to be incorporated into 
these models. This allows simulations to be performed as a multi-scalar level providing a 
detailed dissection and analysis of how changes in the electrophysiology of the cell 
manifest themselves at a multi-cellular level and therefore provides possible insight into 
future direction for experimental studies. 
1.10 Modelling single ion-channels by means of ionic current 
formulations 
 
The first electrophysiological model was constructed by Hodgkin and Huxley on the giant 
squid axon (Hodgkin and Huxley 1952). Developments of atrial cell models are based on 
knowledge of underlying electrophysiology, primarily which ion-channel proteins are 
actively transcribed in the cell allowing the flow of ions to cross the cell membrane. Ion-
channels are pore-forming proteins which regulate the flow of Ca
2+
, K
+
, and Na
+
 ions 
across the bi-lipid cell membrane. Each of these ions has multiple associated ion-channels 
each with its own unique properties which include, time kinetics, voltage dependent 
activation and deactivation. All of these properties can be modelled mathematically in 
accordance with available experimental data. 
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Figure 1.5 Schematic showing a gated ion-channel (A) and pump (B) imbedded in a cell 
membrane, where positive ions are shown as red circles and negative ions are shown as blue 
squares. Panel A shows an activation gate (represented as a lozenge) and an inactivation gate 
(represented as a ball on a chain)  Ai: Shows an ion-channel with a net positive charge above the 
cell membrane, the activation gate, located at the top of the channel is closed preventing the flow of 
ions. Aii: Activation and inactivation gates are open allowing the flow of ions across the cell 
membrane. Aiii: As ions flow through the channel net charge across the membrane is altered 
resulting in the inactivation gate to close, preventing the flow of ions back through the cell 
membrane. Panel B shows the function of an exchanger pump whereby the protein structure allows 
for the passing of ions across the membrane against the ionic gradient. An exchanger pump allows 
ion to be exchanged with an oppositely charged partner from the other side of the membrane. Bi: A 
positive charged ion and negatively charged ion enter the pump from above and below the cell 
membrane respectfully. Bii: Ions are exchanged through the pump. Biii: Ions exit the pump on the 
opposite side from which they entered. 
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1.10.1 Ion-channels and pumps 
 
An individual ion-channel is responsible for the transfer of a specific ion type across the 
cell membrane in the direction of the concentration gradient. However, there is also a sub-
category of ion-channel which allows the flow of ions regardless of direction of this 
gradient; these are referred to as pumps. As pumps allow the flow of ions against the 
concentration gradient, they require a greater energy consumption to function. Ion-
channels are also catagorised by their effect on the net charge of the cell. Inward current 
are those which allow positive ions to enter the cell or negatively charged ions to exit, 
resulting in an increase in cell membrane potential. Conversely, outward current are those 
which result in a net ionic charge exiting the cell thereby reducing membrane potential. 
Ion-channels are further classified by the ions they transport. The simplest form of ion-
channel, which relies on the ionic concentration gradient alone is know as a leakage 
current, and has a fixed conductance value. However, ion-channels currents which are 
modified by the potential difference across the cell membrane are known as voltage-gated 
channels. These channels have activation (allowing the flow of ions) or deactivation 
(preventing the flow of ions) gates. There may also be a time-dependant component to the 
activation and deactivation of ion-channels. A schematic of these ion-channels can be seen 
in Figure 1.5. In addition to ion-channel flow being regulated by there voltage dependant 
ion-channel, they can also be modulated by the presence of various hormones or 
chemicals. For example the IKATP ion-channel is responsible for the flow of potassium 
currents and can be modulated by the presence of the ATP hormone (Ehrlich 2008). The 
alteration of ion-channels in accordance with various external factors may be part of the 
body’s mechanisms to provide a natural cardiac protective effect and are of interest as they 
can be exploited in the development of drug therapies. 
 
1.10.2 Hodgkin-Huxley simulation 
 
The first model of the ion-channels was proposed by Alan Lloyd Hodgkin and Andrew 
Huxley in 1952 on their work on the giant squid axon; for which they received the noble 
prize in 1963 (Hodgkin and Huxley 1952). In their paper they conducted voltage clamp 
experiments on the nerve endings of a giant squid axon. Their work concluded that the 
total current of a cell could be modeled by the following equations. 
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Where I is the total membrane current for a specific ion-channel, V is the membrane 
potential, t is the time, gmax is the maximal conductance, n is the activation gate probability, 
m is the inactivation gate probability, a and b are integer values representing the number of 
activation and inactivation gates respectively,  τn  and τm are the activation and inactivation 
time constants respectively, and n∞ and m∞ are the probability that the n and m gates will 
be open if the system is allowed to run for an infinite amount of time, i.e. reach a steady 
state. Using this modelling technique they concluded that experimental data collected from 
patch clamp recording of the squid axon could be fitted accurately to a hypothetical curve. 
Hodgkin and Huxley found that using the values of 3 and 1 for a and b respectively 
provided an accurate fit. It was subsequently discovered that this corresponded to the 
number of gates each individual ion-channel possessed. These simulation techniques 
remain the foundation of many of the current cardiac models available in the literature 
 
1.10.3 Markov chains 
 
While there has been much success in utilising the Hodgkin-Huxley type formulation to 
develop detailed cell models (Courtemanche, Ramirez et al. 1998; Nygren, Fiset et al. 
1998) the simplified gated hypothesis of an ion-channel either being open or closed state is 
not physiologically accurate. Cellular biologists have concluded that a single ion-channel 
can exist in multiple closed and open states. Therefore recent modelling practices have 
utilisised a Markov chain hypothesis to simulate ion-channel function. An example 
Markov chain formulated for simulating IKur in a canine model is described in Equation 1.2 
(Sridhar, da Cunha et al. 2007). 
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                                  (1.2) 
 
This model permits the ion-channel to be in one of three states, two closed (C1 and C2) 
and one open (O). Each individual ion-channel can exist in only one state and progresses to 
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another state at a rate of α or β. It is possible to model the ion-channel deterministically via 
a series of ODEs. However, solving a set of ODEs describing a markov chain formulation 
is problematic. The large range of timescales present in the ODE system result in the 
equations being extremely stiff in nature, and therefore require advanced numerical 
techniques to solve. In addition modelling ion-channels deterministically does not provide 
a realistic representation of ion-channel kinetics. Modelling the system in a truly stochastic 
manner requires a solution method such implementing the Gillespie algorithm (Gillespie 
1977) whereby the progression of the state of the channel is described by the drawing of a 
random number. 
 
1.11 Atrial cell models 
 
Two well established biophysically detailed computer models of human atrial cell APs by 
Courtemanche et al. (Courtemanche, Ramirez et al. 1998) (hereafter referred to as CRN) 
and Nygren et al. (Nygren, Fiset et al. 1998) (hereafter referred to as NYG) were used in 
this study. Both models were developed in the same year and are based on similar 
physiological data. However, the construction methods by which the models took and 
differenced to the underlying physiology on which the cell models are based resulted in 
dramatic difference in the AP simulated and the stability of the models; simulated APs and 
ionic currents for the CRN and NYG models can be see in Figure 1.7. Although based on 
similar experimental data, the spike-and-dome AP produced by the CRN model and the 
triangular AP produced by the NYG model are strongly regulated by the respective ionic 
currents and biophysical properties considered in the two models. Intracellular ion 
dynamics are also different between the two models, with the NYG model incorporating a 
cleft space. With detailed mathematical descriptions of ionic currents and intracellular ion 
dynamics, the CRN model consists of a 24 variable non-linear coupled ODE system and 
has been widely used in computational studies (Zhang, Garratt et al. 2005; Seemann, 
Hoper et al. 2006; Kharche, Garratt et al. 2008). The 29 variable ODE Nygren model, 
based on the previous LMCG model (Lindblad, Murphey et al. 1996), also consists of 
biophysically detailed descriptions of cell membrane ion currents and intracellular ion 
dynamics. The NYG model is parametrically tuned for stable APs at a pacing frequency of 
1 Hz under basal conditions. It has been used in our previous computational studies, and 
has been shown by others to be functionally similar to the CRN model (Zhang, Garratt et 
al. 2005). Conductance parameters in the CRN model can be manipulated to reproduce the 
NYG model AP (Syed, Vigmond et al. 2005).  However, prolonged pacing of the NYG 
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model, even at low pacing rates, gave rise to errant spontaneous APs. The pacing protocols 
in simulations using both models were therefore altered to avoid such modelling defects.  
1.12 Multi-scale tissue simulations 
While developing electrophysiological models from available experimental data is capable 
of reproducing APs. There remains the issue of performing simulations to quantify how 
changes to the underlying electrophysiology can manifest themselves as AF. This section 
outlines simulation protocols for performing single cell, 1D, 2D, and 3D multi-scale 
simulations using the CRN and NYG models. It is noted that the NYG model was used 
only in simulating the effects of Beta-Blockers (BB) in Chapter 5. The only alteration in 
the simulation protocols for the NYG model was the stimulation strength and duration to 
elicit an AP was altered to -1.3 nA for 6 ms respectfully. In addition, due to the observed 
instability of the NYG model at prolonged pacing the 4
th
 AP was measures instead of the 
10
th
 as described in CRN simulations. 
 
1.12.1 Simulation of AP 
An AP profile from an isolated atrial myocyte was simulated by using a standard pacing 
protocol (Kharche, Seemann et al. 2007) whereby a series of 10 supra-threshold stimuli of 
2 nA/pF and duration of 2 ms are applied to the cells, which can be seen in Figure 1.6A. 
Each stimulus was applied to the cell at a pacing cycle length (PCL) of 1000 ms. Such a 
pacing regime was deemed sufficient to allow the cell models to reach a consistent AP 
profile. The 11
th
 AP was therefore used for measuring the properties of the AP and all 
major currents. Multiple measurements of the AP profile were taken to quantify its 
morphology and study how alterations in these values indicate the possible geneses of AF; 
quantities measured and are indicated in Figure 1.6B. These include AP duration, APD50 
and APD90, which are defined as the time taken from the initial excitation stimuli until the 
AP reached 50% and 90% repolarisation respectfully. The RP was measured as the steady 
state value of the cell membrane potential, which was taken to be the value immediately 
preceding the final AP. Over shoot (OS) is is recorded as the peak membrane potential. 
Maximal upstroke velocity (dV/dtmax) is defined as the maximum gradient of the upstroke 
of the AP.  Simulated CRN and NYG are shown in Figure 1.7. 
 
1.12.2 Construction of APD restitution curves 
APD restitution (APDr) measures the excitation behaviour of atrial cells subjected to 
premature pulses immediately after a previous excitation (Franz, Karasik et al. 1997; Qi, 
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Tang et al. 1997; Kim, Kim et al. 2002; Burashnikov and Antzelevitch 2005; Cherry, 
Hastings et al. 2008). Recent experimental and modelling studies have shown the 
correlation between the maximal slope of APDr greater than unity and instability of re-
entrant excitation waves in 2D and 3D tissues (Xie, Qu et al. 2002; Banville, Chattipakorn 
et al. 2004; ten Tusscher, Mourad et al. 2009). In our study, APDr is computed using a 
standard S1-S2 protocol whereby a series of 10 conditioning pulses (S1) at a PCL of 1000 
ms followed by a premature stimulus pulse (S2) are applied. S1 and S2 have the same 
stimulus amplitude and duration of 2 nA/pF and 2 ms respectively. The time interval 
between the final conditioning excitation and onset of the premature excitation emulates 
atrial diastolic interval (DI), or the time the atrial tissue has for recovery from the previous 
excitation of the premature AP. The APD is measured and plotted in respect of the DI to 
obtain APDr curves. DI is defined as the time duration from the end of the 10
th
 
conditioning AP excitation (defined as the time at which the 10
th
 excitation reached 90% 
repolarisation) and the upstroke (defined as the time at which the AP excitation reached 
maximal upstroke velocity) of the premature 11
th
 excitation. Maximal slopes (MS) is 
defined as the peak gradient of the APDr curves. The cut off PCL is defined as the shortest 
DI at which the cell can illicit a successful AP. The pacing protocol along with constructed 
CRN and NYG APDr curves are shown in Figure 1.8. At large DI, APDr curves have 
negligible slopes and show AP profiles under physiological rates of pacing. At low DI, 
however, the slopes gradients are noticeably increased. 
1.12.3 Construction of ERP restitution curves 
Shortening of atrial APD and ERP are well recognised features of atrial electrical activities 
during AF. ERP is generally measured by using cellular or tissue preparations (Workman, 
Kane et al. 2001; Laurent, Moe et al. 2008). In these simulation studies, the experimental 
protocol as described by Workman et al. (Workman, Kane et al. 2001) was adopted 
whereby ERP and ERP restitution (ERPr) was computed using a S1-S2 protocol with 
stimulus strength and duration of 2 nA/pF and 2 ms respectively. A series of 10 premature 
stimulus pulses (S1) are applied at a given PCL, an 11
th
 premature stimulus (S2) with 
variable time delay (∆T) is applied. ERP is defined as minimal time between S1 and S2 by 
which will elicit a successful AP; successful being defined as an AP which has an 
amplitude of at least 80% of the magnitude of the preceding AP. The constructed ERPr 
curve shown in Figure 1.9 was constructed by plotting ERP as a function of the variable 
PCL.  
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Figure 1.6 Simulated AP pacing protocol using the CRN model and identification of important 
physiological measurements. A: A train of 10 conditioning pulses at a PCL of 1000 ms and 
initiation of a final 11
th
 AP which is recorded for measurements. B: Final two APs from panel A 
where the measurements DI, RP, OS, dV/dtmax,, APD50, and APD90. are indicated. 
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Figure 1.7 Simulated AP and current traces from the CRN (left column) and NYG (right column) 
representing the 11th  AP  from a cell is paced at 1 Hz.  
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Figure 1.8 Simulation protocol for the construction of the APDr,90 curve and representative curves 
for the CRN and NYG models A: Train of 10 preconditioning pulses followed by several 
premature elicited APs as various DIs. B: Final 1.5 s of simulation protocol showing the 10
th
 and 
11
th
 APs, where APD is observed to shorten in relation to the reduction of DI. C: Constructed 
APRr,90 curves for the CRN (solid line) and NYG (dashed line) model. 
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Figure 1.9 Simulation protocol for the construction of the ERPr curves and representative curves 
for NYG and CRN models. A: Train of 10 preconditioning pulses followed by several premature 
elicited APs. B: Final 1.5 s of simulation protocol showing the 10th and 11th APs where the dotted 
line represents 80% of the amplitude of the 10
th
 AP. Amplitude of the 11
th
 AP is observed to 
shorten due to premature stimuli. ERP is measured as the shortest time at which the tissue can elicit 
an AP with amplitude of 80% of the previous C: Constructed ERPr curves for the CRN (solid line) 
and NYG (dashed line) model. 
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1.12.4 Simulation of spatially extended tissues 
 
1D strands of tissue were modeled by incorporating the single cell models into a parabolic 
partial differential equation (PDE) to construct mono-domain spatial models of electrical 
propagation. The PDE has the form: 
 
 ionm IuDtuC −∇=∂∂
2/                                             (1.3) 
 
Where u is cell membrane potential, Cm is cell membrane capacitance, D is the electrotonic 
diffusion coupling between cells simulating the gap junction coupling, u is the membrane 
potential, and Iion is the membrane current. D was taken to be 0.031 mm
2
/ms (Biktashev 
2002)  to give a physiological conduction velocity (CV) of 0.27 mm/ms for a solitary wave 
propagating through atrial tissue. Intracellular distance, represented by the spatial step of 
the spatially extended models, was taken to be 0.1 mm. Such a space step closely relates to 
physiological spacing between human atrial cells and gave stable numerical solutions 
independent of spatial step size. Such a formulation is sufficient for our purposes as we do 
not consider any extracellular potentials, fluids or indeed mechanical activity, for which 
more complex bi-domain formulations have to be adopted (Potse, Dube et al. 2006; 
Whiteley 2007; Vigmond, Weber dos Santos et al. 2008; Linge, Sundnes et al. 2009; 
Morgan, Plank et al. 2009). 
 
1.12.5 Construction of CV restitution curves in a 1D strand of atrial 
tissue 
 
CV restitution (CVr) curves are computed by measuring the speed of propagation of the 
excitation wave front along the simulated 1D homogenous strand of atrial tissue using a 
standard protocol and can be seen in Figure 1.10 (Zhang, Kharche et al. 2008). A series of 
10 conditioning pulses were elicited and allowed to propagate across the strand. The wave 
was initiated by stimulating the end three cells with stimulus strength of 2 nA/pF for 2 ms. 
Conditioning pulses (S1) were applies at a PCL of 1000 s after which a premature pulse 
(S2) was applied. The velocity of propagations of the wave from the S2 stimulus is 
computed by calculated from the time for the excitation wave front to reach the center of 
the strand. The CV of the second propagation wave is plotted as a function of the inter-
pulse duration to construct the CVr curve.  
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Figure 1.10 Simulation protocol for the construction of CVr curves and representative curves for 
the CRN and NYG models. Where rows A, B, and C show the propagation of the excitation wave 
along a 1D strand at inter pulse durations 1000 ms, 500 ms, and 320 ms respectfully. Panels i and 
iii shows a representative voltage time plot for the 50
th
 and 150
th
 nodes respectfully. Panel ii shows 
an image representing the propagation of the wave along the 1D strand with respect to time. Panel 
D shows constructed CVr curves for the CRN (solid line) and NYG (dashed line) model. 
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Figure 1.11 Temporal vulnerability window (TVW) simulations and calculated results for the CRN 
and NYG models. The method for TVW computation is shown in panels A. A conditioning pulse 
propagating from bottom to top of the 1D virtual strand, with a premature stimulus resulting in 
either bi-directional block (Ai), uni-directional block (Aii) or bi-directional propagation (Aiii) 
depending on when during the repolarisation phase it was applied. B: Shows the calculated TVW 
for the CRN and NYG models. 
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1.12.6 Calculation of temporal and spatial vulnerability window 
 
Genesis of re-entrant circuits require tissue to sustain uni-directional block (Quan and 
Rudy 1990). Uni-directional conduction block in atria can lead to genesis of re-entrant 
excitation waves. Temporal vulnerability window (TVW) measures the vulnerability of 
cardiac tissue to genesis of uni-directional conduction block. TVW is computed by 
allowing a single solitary wave to propagate from one end of the 1D tissue to the other. 
After certain duration and in the repolarisation phase in the middle of the tissue, a 
premature pulse is applied. The time window during which the premature pulse elicits uni-
directional propagation block is termed as the TVW. Figure 1.11 illustrates the protocol 
and also shows the measured TVW calculated for the CRN and NYG models.  
 
Spatial vulnerability window (SVW) is quantified by using 2D homogeneous models of 
human atrial tissue. SVW is computed as the minimal atrial substrate size that can sustain 
re-entrant waves. To this end, a sufficiently long pulse as shown in Figure 1.12 is applied 
in the repolarisation tail of the conditioning pulse, giving rise to a figure of “8” re-entrant 
waves. The minimum length that sustains such re-entry is termed as minimum substrate 
(MS). The calculated SVW for the CRN and NYG models is also give in Figure 1.12. 
 
1.12.7 2D tissue modelling, spiral wave re-entry  
 
Models of 2D idealized homogenous atrial tissue were constructed to study the behaviour 
of re-entrant waves. Using the PDE described in Equation 1.3 to construct mono-domain 
spatial models of electrical propagation. The 2D sheets were taken to be 37.5 mm x 37.5 
mm approximating the size of the human atria. In simulations, re-entrant waves are 
initiated by using a cross-field stimulation protocol. After allowing a planar wave to 
sufficiently propagate through the 2D sheet, a cross-field stimulus is applied so as to 
initiate re-entry (Kharche, Seemann et al. 2007). Upon initiation of a re-entrant wave in the 
middle of the tissue, the re-entrant waves are allowed to evolve. In total 6 s of electrical 
activity in the 2D sheets was simulated and characterized by re-entrant wave tip 
trajectories, life spans (LS), and a time series plot of the membrane potential of selected 
nodes whereby a frequency analysis yielded the PSD indicating the dominant frequencies 
(DF) of the electrical excitations. The 2D simulations using the CRN model are shown in 
Figure 1.13.  
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Figure 1.12 SVW simulations and calculated values for the CRN and NYG models. The 2D Panels 
shown in rows A and B illustrate the simulation protocol. In panels A the stimulus is of insufficient 
length to initiate re-entry. In panels B the stimulus is of sufficient length initiates a figure of eight 
re-entry. The critical value of the stimulus length at which re-entry is initiated is measured as the 
MS. C: Shows calculated MS for the CRN and NYG models. 
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Figure 1.13 Simulation of re-entry in a 2D idealised sheets of virtual atrial tissue. A: 
Representative frames from 2D simulations using the CRN model B: Spiral wave tip trace C: AP 
trace taken from a representative cell in the 2D atrial sheet, re-entry is observed to terminate after 
1.4 s. D: Corresponding PSD for the representative AP trace in panel C, where the frequency of 
maximum power is shown as 3.6 Hz. 
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Figure 1.14 3D scroll wave simulations. A: Representative frames from 3D simulations using the 
CRN model B: AP trace taken from a representative cell in the 3D atrial geometry, re-entry is 
observed to terminate after 4.2 s D: Corresponding PSD for the representative AP trace in panel C, 
where the frequency of maximum power is shown as 3.1 Hz. 
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1.12.8 3D scroll waves in the atria 
 
The 3D anatomically detailed spatial model of human female atria as was developed in a 
previous study (Seemann, Hoper et al. 2006). It is based on the anatomical geometry of the 
human atria reconstructed from the visible human project (Ackerman, 1991; Ackerman and 
Banvard 2000). The anatomical model consists of electrically homogeneous atrial tissue, 
the SA node and conduction pathways.  The SA node is the main pacemaker wherefrom 
cardiac electrical excitation originates. The conduction pathways are electrically and 
structurally heterogeneous and assist in normal conduction of electrical excitation in the 
human atrium. In our studies, we investigate  re-entrant waves and therefore do not 
consider SA node electrical activity, nor the heterogeneity associated with the conduction 
pathways. All cells in our 3D anatomical model simulations are considered to be 
electrically homogeneous. The 3D model has a spatial resolution of 0.33 mm x 0.33 mm x 
0.33 mm. Although the 3D simulations have a small dependence on such a space step, the 
total simulated time of electrical activity was less than 6 s and no apparent differences 
were observed in preliminary simulations at 0.1 mm and 0.33 mm up to such time scales. 
The re-entrant waves were initiated using a protocol similar to the 2D case. The planar S2 
stimulus was applied at a location in the RA to reduce boundary effects and interference 
from anatomical obstacles. The RA was chosen to be ideal as it offers minimal anatomical 
defects interfering with the initial evolution of the re-entrant waves. The activity of the 
atria were characterised by LS of re-entrant waves, time-traces were recorded from 
selected nodes, and frequency analysis was preformed to construct a PSD to determine of 
DF of the re-entrant waves. Results under control conditions are shown in Figure 1.14 
where lifespan was measure to be around 4.2 s and a DF of 3.1 Hz was calculated. 
 
1.12.9 Numerics, algorithms and visualisation 
 
The simulations in this thesis were performed by utilising a simulation toolkit custom 
deigned for performing multi-scale simulations (Kharche, Seemann et al. 2007). As the 
CRN model consists of multiple timescales the ODE system is stiff. However, the toolkits 
integration method of an explicit Euler method with a time step of 0.05 ms was found to 
provide a sufficiently stable solution when implemented. The toolkit also utilises check 
pointing wherever possible to limit computational expense of the simulations. The 1D and 
2D spatially extended PDE models were solved using the explicit Euler method with a 3 
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and 5 node Laplacian operator in 2D respectively; a time step was 0.005 ms and space step 
0.1 ms proved sufficient for a stable solution. In the 3D case a 7-node approximation for 
the Laplacian operator was implemented and the space step was taken to be the anatomical 
model spatial resolution of 0.33 mm, which gave stable solutions with a time step of 0.05 
ms. The 2D and 3D spatial models are large with 140625 and more than 26 x 10
6
 nodes 
respectively. Parallelisation is therefore an important part of cardiac simulations. Solvers 
that used shared memory parallelism (OpenMP) and large distributed memory parallelism 
(MPI) were developed in our laboratory (Kharche, Seemann et al. 2008). The local high 
performance computing facilities with 208 CPUs system with distributed memory 
connected by a single rail Quadrics QsNetII interconnector and with MPI was used. The 
full geometrical model demands very large amounts of contiguous memory. 3D Atrial 
tissue geometry occupies about 8% geometry of the total data set, due to atrium being thin 
walled with large holes of atrial chambers and vena caves. We re-structured the computer 
code such that only atrial nodes, i.e. only 8% of the total 26 million nodes and related 
information are stored in the computer memory. This improved efficacy of memory usage. 
By re-numbering the real atrial nodes we are not storing any data points that are not atrium. 
The memory required is reduced to less than 10 GB in the 3D case, and the required 
computer floating point operations (flops) are also reduced. 
 
The 3D simulations produce large data sets of more than 30 GB. Traditionally this output 
is then post-processed to obtain measures quantifying the simulation, e.g. scroll wave 
filament meander, and to visualise the dynamics of the electrical propagations. Each output 
file consists of a binary data file of approximately 150 MB size. Efficient visualisation of 
the 3D data was developed created by using the visualisation package Advanced 
Visualisation System (AVS) developed by Manchester Visualisation Centre. This is 
versatile high level graphical software with a high level of functionality. 3D figures were 
produced using diamond shaped glyphs, each of which was colour coded with a scalar 
value, namely the value of voltage at that location.  For smaller visualisation jobs, e.g. 2D 
visualisation, we have used MATLAB due to its functionality and transparent scripting. 
Development of visualisation scripts using MATLAB is relatively straightforward with a 
high level of functionality. MATLAB is also available to our laboratory locally. Having 
successfully developed 2D visualisation pipelines using MATLAB, AVS as a high level 
visual programming environment is also versatile and the results obtained using MATLAB 
can be replicated by AVS.  
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1.10 Simulating disease and AF 
 
Several ion-channel dysfunctions are associated with AF (Abriel and Kass 2005; Abriel 
2007). In addition the effects of age have been studied in a tissue specific study by Zhao et 
al. (Zhao, Trew et al. 2009). There is a large amount of interest in the modelling 
community to simulate how changes in the electrophysiology of a cell due to such external 
factors are manifested as AF. The effects of multi-channel dysfunction induced AF has 
been studied in our laboratory (Kharche and Zhang 2008). Initiation of re-entrant waves is 
often due to triggers, and the underlying mechanisms have also been investigated in a 
limited way (Tveito and Lines 2008). In a novel cellular automata modelling study, 
Reumann et al. and others (Haghjoo 2007; Reumann, Bohnert et al. 2007) showed the 
existence of “snakes” and “worms” in the human atrium. Simulation facilitates the 
dissection of the underlying electrophysiological causes (Zhang, Garratt et al. 2005) of 
tissue and organ level AF (Kharche, Garratt et al. 2008). Simulation studies remain focused 
on investigating the causes of initiation and stabilisation of re-entrant waves (Xie, Qu et al. 
2002). Although attempts have been made to simulate the whole atrium in anatomical and 
biophysical detail (Blanc, Virag et al. 2001), it has not been achieved to sufficient accuracy 
to be clinically relevant. Small animal research also plays an important role in 
understanding of cardiac electrophysiology and the simulation of AF is no exception. The 
ability to simulate pharmacological intervention, for example the effects of INa block which 
results reduction of APD (Kneller, Kalifa et al. 2005), also provides an aim for modellers. 
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Table 1.1. Quantitative summary of the multi-scale simulations for the CRN and NYG 
atrial cell models. 
Model Quantity CRN NYG 
Resting potential 
(mV) 
-80.80 -73.7 
APD90 (ms) 314.2 221.3 
APD50 (ms) 210.6 134.4 
Overshoot (mV) 24.7 29.5 
dV/dtmax (mV/ms) 217.1 141.7 
APDr maximal 
slope 
1.3 0.64 
Cell 
ERP (ms) 
(stimulus interval 
~ 1 s) 
327.9 216.0 
 Cut off BCL (ms) 328.6 200.0 
CV (mm/ms) 0.26 0.27 
Cut off S2 (ms) 320 213 
TVW (ms) 14.6 12.1 
1D 
Wavelength (mm) 81.7 60.2 
LS (s) 1.4 - 
DF (Hz) 3.6 - 
Tip meander area 
(cm
2
) 
5.25 - 
2D 
SVW (mm) 49.2 27.5 
LS (s) 4.2 - 
3D 
DF (Hz) 3.1 - 
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Chapter 2 
Simulating the arrhythmogenic effects of the KCNQ1 (S140G) 
gene mutation in human atria 
 
2.1 Introduction to the KCNQ1 gene mutation 
 
Whilst the underlying mechanisms for the genesis of AF are yet unclear, organic cardiac disease 
(Danicek, Theodorovich et al. 2008; Tanabe, Kawamura et al. 2009) and AF induced electrical 
remodelling of ion-channels (Bosch, Zeng et al. 1999; Workman, Kane et al. 2001; Ashcroft 
2006) are believed to be among major factors responsible for initiating and sustaining AF. These 
underlying risk factors increase in prevalence with age and are the primary reasons why the 
incidence of AF rises substantially in the elderly. Lone AF patients, who have no underlying 
disease indicating an increased risk of AF, are still at risk of sudden episodes of AF. Lone AF is 
also observed in much younger demographics. These patients have characteristic solitary gene 
defects which predispose them to the condition (Fox, Parise et al. 2004; Campuzano and 
Brugada 2009). Recent experimental studies have identified several gene mutations in familial 
AF patients (Yang, Xia et al. 2004; Xia, Jin et al. 2005; Olson, Alekseev et al. 2006; Otway, 
Vandenberg et al. 2007). These mutations have been identified to alter the electrophysiology of 
key ion-channels responsible for repolarisation of atrial myocytes. Recently a mutation has been 
identified in familial AF patients in the KCNQ1 gene that encodes the pore forming -subunit of 
the cardiac slow-delayed rectifier potassium channel (IKs) (Lundby, Ravn et al. 2007; Ravn, 
Aizawa et al. 2008; Restier, Cheng et al. 2008). Chen et al. (Chen, Xu et al. 2003) clinically 
identified a familial missense mutation of KCNQ1 at nucleotide 418 from adenine to guanine, 
which results in a change of amino acid from serine to glycine at 140 (S140G mutation). 
Functional analysis of the co-expression of wild type (WT) and S140G mutant type (MT) 
KCNQ1 with KCNE1 revealed a mutation induced increase of IKs (Chen, Xu et al. 2003). IKs is 
an important outward potassium current regulating late repolarisation of action potentials (APs) 
in cardiac cells. Abnormality of IKs has been found in various cardiac diseases including long QT 
(Lundby, Ravn et al. 2007; Zhang, Yin et al. 2008) and short QT (Bellocq, van Ginneken et al. 
2004) syndromes. It has been shown that gain-in-function of IKs due to KCNQ1 V93I mutation in 
SQT-2 syndrome dramatically abbreviates human ventricular AP duration (APD) and augments 
intra-ventricular heterogeneity increasing susceptibility to arrhythmia (Zhang, Kharche et al. 
2008). However, the mechanisms by which the gain-in-function of IKs caused by the KCNQ1 
S140G mutation promote and perpetuate atrial arrhythmia have not been elucidated. The aim of 
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this study was to quantify the pro-arrhythmogenic effects of the KCNQ1 S140G mutation in the 
human atria at cell, tissue and whole-organ levels. 
2.2 Methods 
 
This section outlines the modification of the CRN model (Courtemanche, Ramirez et al. 1998) to 
simulate the alterations to IKs due to the KCNQ1 mutation. Experimental data provided by 
(Chen, Xu et al. 2003) allowed the mutation to be simulated as an addition of a voltage 
dependant leakage current. Simulations were performed as described in Chapter 1 to quantify the 
arrhythmogenic effects of the mutation at the single cell, 1D strand, and 2D idealized atrial sheet 
levels, as well as in an anatomically detailed 3D atria. 
2.2.1 Model of IKs and atrial cell APs 
  
The CRN model  (Courtemanche, Ramirez et al. 1998) was used in this simulation study. It was 
chosen as it incorporates available human atrial cell and membrane data and reproduces human 
atrial electrical APs and APD rate dependence. The model has been found to be well suited to 
study re-entrant arrhythmias in human atrium (Pandit, Berenfeld et al. 2005; Seemann, Hoper et 
al. 2006; Kharche, Garratt et al. 2008). In the CRN model, the IKs potassium (K
+
) current is 
modeled as: 
2
( )Ks Ks kI g n V E= −                                                           (2.1) 
 
where gKs is the current conductance  (CRN Control gKs = 0.129 nS/pF), n is the activation gate, 
V is the membrane voltage, and Ek is the K
+
 reversal potential. The steady state properties of the 
activation gate, n, are described in the original CRN model. The model was modified to 
incorporate changes in IKs due to the KCNQ1 S140G mutation (Chen, Xu et al. 2003), as shown 
in Figure 2.1A. These changes include (i) a large increase of IKs current density; and (ii) a large 
IKs at hyperpolarized potentials not seen under WT conditions. Upon analysis of the experimental 
I-V data (Hong, Piper et al. 2005), equation (2.1) was modified by adding a non-gated voltage 
dependent leakage component, to model mutant I′Ks as: 
 
( )' 'Ks Ks Ks revI I g V Eϕ= + −                                                  (2.2) 
 
where gKs has the same value as in the Control case, IKs is the current conductance,  E’rev is the 
reversal potential of the leakage component, which was estimated to be -75.3 mV. φ is a scaling 
factor between 0 (WT; Control) and 1 (MT; homozygous), enabling simulation of possible 
intermediate heterozygous mutant conditions.  
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Modifications to IKs for the mutant condition were validated by the reproduction of experimental 
IKs I-V relationships (Chen, Xu et al. 2003) and IKs time traces during voltage clamp under the 
WT (φ = 0) and the MT (φ = 1) conditions. Following experimental voltage clamp protocol as 
given in Chen et al. (Chen, Xu et al. 2003), the cell membrane potential was first held at -80 mV 
for 1 s, and then clamped at test potentials ranging from -130 mV to 50 mV, each for a duration 
of 3 s. Amplitudes of IKs at the end of the voltage clamp pulses were plotted as a function of the 
step voltages to obtain I-V relationships (Figure 2.1A). Experimental and simulated time traces 
of IKs during voltage clamp are shown in Figure 2.1, B-E. In both the WT and MT cases, the 
simulated IKs I-V relationships closely approximate experimental data. In the following, 
simulation results are presented for φ = 0 (WT), φ = 0.1 (10% MT), φ = 0.25 (25% MT) and φ = 
1 (MT) conditions. 
 
2.3 Results 
 
This section provides a detailed description of the results obtained from performing multi-scale 
simulations on the electrophysiological effects of the KCNQ1 S140G mutation. A summary of 
the functional effects of the mutation on simulated human atrial electrical activity are listed in 
Table 2.1. 
2.3.1 Effects of increased IKs on atrial APs 
 
Increased IKs due to the KCNQ1 S140G mutation abbreviated human atrial APs as shown in 
Figure 2.2A. The measured APD was 314.2 ms under WT condition and 22.4 ms under the MT 
condition. The APD reduction was due to the mutation induced increase in IKs (Figure 2.2B), and 
is associated with a decrease in the delayed rectifier K
+
 current, IKr (Figure 2.2C) and Ito (Figure 
2.2D). A marginal reduction of the L-type calcium current, ICaL, (Figure 2.2F) was observed. 
Since the mutation was seen to cause such a dramatic abbreviation of the APD, the effects of 
intermediate increases in the leakage component of IKs, mimicking homozygous conditions, were 
investigated by gradually increasing φ. An increase in φ resulted in a monotonic decrease in the 
APD (Figure 2G). At φ = 0.1 (10%) and φ = 0.25 (25%), the measured APD was 147.5 ms and 
79.32 ms respectively.  
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Figure 2.1 Experimental and simulated IKs under WT and MT conditions where experimental data 
are from Chen et al. (Chen, Xu et al. 2003). A: Experimental IKs I-V relationships under WT (solid 
circles) and S140G mutant IKs (open circles) superimposed upon simulated I-V relationships for 
WT and MT cases (solid lines). B: Experimental IKs current traces under WT conditions. C: 
Simulated current traces under WT conditions. D: Experimental current traces under MT 
conditions. E: Simulated current traces under MT conditions. 
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Table 2.1. Quantitative summary of the effects of the KCNQ1 (S140G) mutation. 
Model Quantity WT 
MT 
(φ=0.1) 
MT  
(φ=0.25) 
MT 
Resting potential 
(mV) 
-80.80 -80.01 -78.74 -76.88 
APD90 (ms) 314.2 147.5 79.3 22.4 
Overshoot (mV) 24.7 24.07 23.05 18.11 
dV/dtmax (mV/ms) 217.1 214.17 208.58 193.44 
APDr maximal 
slope 
1.3 0.6 0.38 0.05 
Cell 
ERP (ms) 
(stimulus interval 
~ 1 s) 
327.9 169.1 109.5 56.0 
 Cut off BCL (ms) 328.6 184.3 126.6 44.9 
CV (mm/ms) 0.26 0.26 0.26 0.258 
Cut off S2 (ms) 320 152 95 46 
TVW (ms) 14.6 15.2 14.7 14.6 
 
Wavelength (mm) 81.7 38.4 20.6 5.78 
LS (s) 1.4 > 10 > 10 > 10 
DF (Hz) 3.6 7.1 9.8 16.1 
Tip meander area 
(cm
2
) 
5.25 1.10 0.58 0.32 
2D 
SVW (mm) 49.2 7.45 6.15 0.6 
LS (s) 4.2 >6 - - 
3D 
DF (Hz) 3.1 8.9 - - 
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Figure 2.2. Simulated AP profiles and current traces under WT (blue line), and MT conditions 
where simulated data for φ = 0.1 (green line), φ = 0.25 (purple line) and φ = 1 (red line) are shown 
in panels A-F. A: AP profiles. B: IKs current profiles during APs. C: IKr current profiles during APs. 
D: Ito current profiles during APs. E: IK1 current profiles during APs. F: ICaL current profiles during 
Ps. G: Changes in APD as the modeling parameter φ is increased from 0 (WT) to 1 (MT) condition.  
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Figure 2.3 Simulated restitution profiles and temporal and spatial VW under WT (blue), and MT 
conditions where simulated data for φ = 0.1 (green), φ = 0.25 (purple) and φ = 1 (red) are shown in 
panels A-F. A: APDr, B: maximal slope of the APDr curves, C: ERPr, D: CVr, E: Temporal VW, 
F: spatial VW. 
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2.3.2 Effects of increased IKs on APD and ERP restitutions 
 
The effects of the increased IKs due to the KCNQ1 S140G mutation on atrial APD restitution are 
shown in Figure 2.3A. Across the range of DI, the measured APD under the MT condition was 
considerably smaller than in the WT condition. MT conditions flattened the APDr curves. The 
measured maximal APDr slopes were 1.3 (WT), 0.6 (φ = 0.1), 0.38 (φ = 0. 25), and 0.05 (φ = 1) 
conditions (Figure 3B). Such a mutation-induced loss in the rate-dependent adaptation of APD, 
indicated by flattened APDr curves, was similar to that observed in chronic AF patients (Osaka, 
Itoh et al. 2000; Watanabe, Masaki et al. 2002). This suggests an increase in the ability of the 
atrial cells to support high pacing rate electrical excitations. 
 
The mutation induced increase in IKs reduced atrial ERP (Figure 2.3C), which decreased from 
327.9 ms in the WT condition to 169.1 ms, 109.5 ms, and 56 ms under φ = 0.1, φ = 0.25, and φ = 
1 conditions respectively, as computed at a PCL of 1 s. The cut-off PCL of the ERP curve under 
WT conditions was 328.6 ms. The mutation shifted the ERP restitution curves leftward, 
measuring 184.3 ms, 126.6 ms, and 44.9 ms for φ = 0.1, φ = 0.25, and φ = 1 conditions 
respectively, again demonstrating an increase in the ability of the atrial cells to support high rate 
electrical activities. 
 
2.3.3 Effects of increased IKs on intra-atrial conduction velocity and tissue’s 
temporal and spatial vulnerability 
 
CVr curves are shown in Figure 2.3D. Under WT conditions the CV at a PCL of 1000 ms was 
measured to be 0.26 mm/ms. When φ = 0.1 and φ = 0.25 the CV remains unchanged from WT 
conditions. However, when φ = 1 there was a reduction in CV to 0.258. In addition to this 
reduction in CV, the mutation facilitated high excitation rate wave propagation. This is shown in 
Figure 2.3D by the leftward shift of the CVr curves. Under WT conditions the cut-off PCL was 
measured to be 320 ms, whereas under φ = 0.1, φ = 0.25, and φ = 1 MT conditions the cut-off 
PCL was 152 ms, 95 ms, and 46 ms respectively. This indicates that increasing the level of the 
mutation through augmenting the parameter φ increases the ability of the tissue to sustain 
electrical wave propagations at ever higher excitation rates. 
 
The measured TVW are shown in Figure 2.4E. Under WT conditions the VW was measured to 
be 14.6 ms. For φ = 0.1, φ = 0.25, and φ = 1 the VW was measured at 15.2 ms, 14.7 ms, and 14.6 
ms respectively. The alterations to VW due to the mutation were nominal. 
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Measured spatial vulnerability of atrial tissue in the 2D model is shown in Figure 2.3F. Under 
the WT condition, the measured minimal substrate size was 49.2 mm. Under the MT conditions, 
the measured minimal size decreased by 84.8% to 7.45 mm when φ =0.1, by 87.5% to 6.15 mm  
when φ =0.25, and was lower than 0.6 mm in the φ = 1 case. Thus, mutant IKs caused a marked 
reduction in the substrate required to induce and sustain re-entry, demonstrating a remarkable 
increase in the susceptibility of the tissue to arrythmogenesis. 
2.3.4 Effects of increased IKs on the dynamical behavior of re-entrant 
excitation waves in 2D model 
 
Figure 2.4 shows that increased IKs stabilized re-entrant spiral waves, which led to sustained re-
entrant excitation in a limited atrial mass. In the WT condition, the initiated spiral wave was 
unstable. The tip meandered in a large area, which led to self-termination when it meandered out 
of the model boundaries or collided with its own repolarisation tail. Core traces, representative 
time traces and PSD are shown in Figure 2.5. The measured LS of spiral waves was 1.4 s under 
WT conditions. Power spectrum analysis of the recorded local electrical activity revealed a peak 
frequency of 3.6 Hz for WT.  Under MT conditions (φ =0.1 and φ =0.25), re-entrant waves were 
stable, persistent and had limited meander throughout the 6 s simulation. Power spectrum 
analysis of the recorded electrical activity from the tissue revealed a peak frequency of 7.1 Hz 
and 9.8 Hz for φ = 0.1 and φ = 0.25 respectively. Under the homozygous MT φ = 1 condition the 
spiral wave was highly stable with a DF recorded as 16.1 Hz.  
2.3.5 Erratic re-entrant electrical excitation waves in the 3D atria 
 
Re-entrant excitation waves (scroll waves), representative time traces and PSD, of the 3D 
anatomical model of human atria are illustrated in Figure 2.6 and Figure 2.7 respectfully for the 
WT and MT (φ=0.1) conditions. Under the WT condition, the scroll wave broke up into multiple 
re-entrant wavelets, with each meandering in a large area of the tissue leading to self-termination 
at 4.2 s. The observed self-termination of scroll waves was independent of the initiation location. 
Under the MT condition, the scroll wave also broke into multiple wavelets, each propagating 
erratically due to interaction with the complex atrial anatomy. The re-entrant excitations 
persisted throughout the duration of the simulation period of 6 s. The dominant frequency in the 
MT case was much higher (~ 8.9 Hz at φ = 0.1) than under the WT condition (3.1 Hz). 
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Figure 2.4 Top panels show results from 2D re-entrant wave simulation under WT condition; the 
second row of panels show results for φ = 0.1 conditions; the third row of panels show results for φ 
= 0.25 conditions and the bottom row show results for φ = 1. Frames from the 2D simulation at 
time t = 1 s (column I), time t = 1.5 s (column II) and time t = 2 s (column III) are shown. 
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Figure 2.5 2D spiral wave tip traces (panel i), representative AP traces taken from 2D 
simulations (panel ii), and power spectrum density showing frequencies of maximal power 
(panel iii) under A: WT, B: φ = 0.1 , C: φ = 0.25, D: φ = 1 conditions. 
 
 
 
 
 
 
 
 61 
 
 
 
 
Figure 2.6 Simulation of scroll waves in the 3D virtual human atrium. Left column shows 
representative frames from the simulation under WT condition and right column shows frames 
from the simulation under MT (φ = 0.1). Row I shows frames at time t = 1 s, in Row II at time t = 2 
s, Row III at time t = 3 s and Row IV at time t = 4 s.  
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Figure 2.7 Traces taken from 3D simulations (panel i), and PSD showing frequencies of maximal 
power (panel ii) under A: WT, B: φ = 0.1 conditions. 
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2.4 Discussion and Conclusion 
 
Due to a lack of phenotypically accurate experimental models, the mechanisms by which the 
KCNQ1 S140G mutation influences atrial cellular electrophysiology and AF susceptibility at the 
tissue level have not been investigated.  In the present study, a computation model was used to 
gain insights into the mechanisms underlying the genesis and maintenance of AF in patients with 
the KCNQ1 S140G mutation.  The major findings are: (i) the KCNQ1 S140G mutation increased 
the IKs by inducing a voltage dependent leakage component. This is similar to the constitutive 
leakage current of IKs arising from KCNQ1 V141M mutation responsible for atrial fibrillation 
and short QT syndrome (Hong, Piper et al. 2005); (ii) the mutation induced gain in IKs 
abbreviated and flattened APD and ERP restitutions, leading to a loss in rate dependent 
adaptation of APD and ERP; (iii) the changes in cellular electrophysiology modulated the tissue 
level atrial conduction which facilitated high rate conduction, and increased tissues’ temporal 
and spatial vulnerability. As a consequence, the tissues’ susceptibility to AF genesis and 
maintenance was increased; (iv) the gain in IKs stabilized re-entry, allowing more wavelets to 
persist and co-exist in a given volume of tissue, leading to more irregular and high frequency 
atrial excitation.  
2.4.1 Mechanisms of pro-fibrillation of the KCNQ1 S140G mutation 
 
Shortening of atrial ERP has been demonstrated to be pro-fibrillatory, as seen in the effects of 
vagal stimulation (Liu, Guo et al. 2009), acetylcholine (Voigt, Maguy et al. 2008), or adenosine 
(Turley, Murray et al. 2008) on initiation of AF.  In the case of the KCNQ1 S140G mutation, the 
increased IKs abbreviated atrial APD and ERP.  In turn, the shortened ERP led to reduced 
excitation wave wavelengths facilitating high rate intra-atrial conduction, allowing more re-
entrant wavelets to persist in a limited atrial mass. In the study of Chen et al., AF persisted in 
individual patients with the mutation once it appeared. This is consistent with our simulation that 
re-entry sustained the mutant condition (φ > 0.07).  The genesis of AF in those patients may be 
attributed to the increased susceptibility of atrial tissue to re-entry. Tissue susceptibility to re-
entry can be indexed by its temporal and spatial vulnerability. While temporal vulnerability is 
mainly determined by the repolarisation phase of APs (Shaw and Rudy 1995), spatial 
vulnerability is mainly determined by the wavelength of the excitation wave, defined as the 
product of CV and APD. In our simulations, the KCNQ1 S140G mutation increased the spatial 
vulnerability of the tissue by markedly decreasing the critical size of the re-entrant substrate due 
to abbreviated APD and ERP. Consequently, the susceptibility of the atrial tissue to maintain re-
entry was increased.  
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2.4.2 Limitations 
 
The CRN model was used here to simulate cellular electrical AP of human atrial myocytes and 
its limitations have been discussed elsewhere (Courtemanche, Ramirez et al. 1998).  In the multi-
cellular tissue model, homogeneous cellular electrical properties and isotropic cell-to-cell 
electrical coupling are assumed.  However, intrinsic electrical heterogeneity in cellular electrical 
properties (Hong, Piper et al. 2005) and anisotropic intercellular electrical coupling play 
important roles in the initiation and perpetuation of re-entry. Another limitation is that AF-
induced electrical re-modelling was not considered (Bosch, Zeng et al. 1999; Workman, Kane et 
al. 2001; Zhang, Garratt et al. 2005; Kharche and Zhang 2008) as well as gap junctional re-
modelling (Jongsma and Wilders 2000; van der Velden, Ausma et al. 2000), which influences 
the mechanisms of AF. However, these limitations are not anticipated to influence the 
fundamental conclusions about the mechanisms by which the KCNQ1 S140G mutation increases 
arrhythmic risk. 
2.4.3 Mutant IKs and cardiac arrhythmia – relevance to previous studies 
 
Abnormality in IKs arising from KCNQ1 mutations has been identified in various cardiac 
diseases that include the LQT (Lundby, Ravn et al. 2007; Zhang, Kharche et al. 2008) syndrome, 
the SQT (Bellocq, van Ginneken et al. 2004) syndrome and atrial fibrillation (Brugada, Hong et 
al. 2004; Hong, Piper et al. 2005; Ellinor, Petrov-Kondratov et al. 2006; Restier, Cheng et al. 
2008; Abraham, Yang et al. 2009; Das, Makino et al. 2009) . Significantly, the gain-in-function 
of IKs associated with KCNQ1 variants can produce overlapped phenotypes of SQT and AF 
(Bellocq, van Ginneken et al. 2004; Restier, Cheng et al. 2008). Patients with these augmented 
IKs mutations exhibit shortened atrial and ventricular refractory periods, and an increased 
susceptibility of atrial and ventricular fibrillation. It was hypothesized that a gain-in-function of 
IKs results in a shortened APD and ERP, which facilitates multiple re-entrant circuits in atrial and 
ventricular fibrillation. In our previous study (Zhang, Garratt et al. 2009) we have shown that an 
augmented IKs arising from KCNQ1 V307L mutation (SQT-2) shortened ventricular APD and 
ERP, increased intra-ventricular heterogeneity, led to abbreviated QT interval, and increased 
ventricular susceptibility to arrhythmia. The present study is the first to elucidate the functional 
impacts of the KCNQ1 S140G mutation in promoting AF. 
 
There is an increasing awareness of the molecular basis underlying the mechanisms of AF. 
Particular emphasis has been placed on AF-induced electrical re-modelling which produces a 
predominant pro-fibrillatory ERP reduction (Yang, Snyders et al. 1997; Hong, Piper et al. 2005; 
Olson, Michels et al. 2005; Xia, Jin et al. 2005; Olson, Alekseev et al. 2006; Otway, Vandenberg 
et al. 2007; Ravens and Cerbai 2008; Restier, Cheng et al. 2008). Our data indicate that in the 
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case of the KCNQ1 S140G mutation, the resulting ERP reduction not only stabilizes re-entry, 
but also increases the susceptibility of human atrial tissue to the genesis of re-entry. Our study 
therefore substantiates a causative link between the KCNQ1 S140G mutation and AF.  
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Chapter 3 
Effects of elevated Homocysteine on the electrical 
activity of the human atrium: A simulation study 
 
3.1 Introduction to the Homocystein hormone 
 
Homocystein (Hcy) is a naturally occurring amino acid present in the human body. Typical 
diets contain trace amounts of the amino acid and the majority of Hcy found in the body is 
biosynthesized as part of the ‘methionine cycle’, the process by which cells metabolize the 
essential amino acid methionine. The total concentration of Hcy within a cell is strictly 
regulated and any excess produced is transported into the body’s plasma. The role that Hcy 
plays in the normal functioning of the body is complex and is still not fully understood. 
However, it has been clinically observed that elevated levels of Hcy are associated with 
coronary, cerebral, and peripheral vascular disease; renal disease, dementia neural tube 
defects, and other disorders (Williams and Schalinske). It has also been associated with 
arteriosclerosis and coronary heart disease (CHD). The first evidence that elevated levels 
of Hcy could be a possible risk factor for CHD was linked when Mudd identified a patient 
with a deficiency of the enzyme cystathionine β-synthase (CBS) with elevated levels of 
Hcy, a condition referred to as homocystinuria (Mudd, Finkelstein et al. 1964). 
Subsequently McCully identified two further patients, one suffering from CBS and the 
other possessing a different enzymatic abnormality also leading to homocystinuria. As both 
patients were identified with arterial damage, and McCully concluded that the risk factor 
resulting in arterial damage were a direct result of elevated levels of Hcy (McCully 1969). 
It has only recently been proven conclusively that elevated levels of Hcy result in an 
increased risk of  CHD (De Bree, Verschuren et al. 2002). 
 
Although several underlying genetic conditions are associated with elevated levels of Hcy, 
it has also been observed that Hcy concentration rises with age. In men, this is thought to 
be due to increased muscle mass due to the ageing process resulting in augmented 
creatine/creatinine synthesis (Andersson, Brattstrom et al. 1992). In women, increased Hcy 
is thought to be primarily due to hormonal imbalances due to the onset of the menopause 
(Wouters, Moorrees et al. 1995). Lifestyle choices have also been identified as causes of 
increased  Hcy concentrations, including coffee, smoking, and alcohol (Nygard, Vollset et 
al. 1995; Nygard, Refsum et al. 1997; Halsted 2001). It is now accepted that an elevated 
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level of Hcy is a risk factor for athlersocsis and consequently strokes. Recent experimental 
studies have found that elevated levels of Hcy above normal physiological concentration (5 
– 20 µmol/L) is associated with alterations in the electrophysical properties of ion channels 
in human atrial myocytes. Ion channels affected were identified to include the down-
regulation of the ultra-rapid potassium current (IKur) and transient outward potassium 
current (Ito), and up-regulation of the inward rectifier potassium current (IK1) (Cai, Gong et 
al. 2007). Because these potassium currents play an important role in atrial repolarisation, 
alterations to them produce an imbalance between the depolarization and repolarisation 
currents, which may produce a disturbance to atrial excitation wave conduction. Previous 
computational studies have shown that a decrease in the depolarizing currents or an 
abnormal increase in the repolarising currents can lead to erratic wave propagation in the 
human atria resulting in atrial fibrillation (Zhang, Garratt et al. 2005; Kharche, Garratt et 
al. 2008). However, the pro-arrhythmic potential of the Hcy induced electrical changes to 
the potassium current have not yet been substantiated  
 
In this study, the effects of an elevated level of the Hcy hormone on atrial electrical 
activities are investigated. Biophysically-detailed computer models of human atria at 
multi-scale levels that include cellular, 1D tissue, and 3D anatomical organ models of 
human atria are utilized. 
3.2 Modelling elevated levels of the Homocystein hormone 
 
The biophysically detailed CRN model was implemented in the study and series of multi-
scale simulations were performed as described in Chapter 1 to quantify how elevated levels 
of the Hcy hormone result in the onset of AF. Experimental data from Cai et al. (Cai, Gong 
et al. 2007) were incorporated into the single cell model. Hcy was observed to result in 
electrical alterations of several potassium ion channels. It was found that Hcy augments the 
inward rectifying potassium channel conductance (gK1), while reducing the ultra rapid 
potassium channel conductance (gKur) and the transient outward potassium channel 
conductance (gto). However, it does not affect the kinetics of these channels. Based on the 
experimental data (Cai, Gong et al. 2007), the dose dependent alterations to the maximum 
channel conductance of gK1, gKur and gto in the Courtemanche et al. model (Courtemanche, 
Ramirez et al. 1998) are summarized in Table 3.1. The original and modified CRN models 
are used to simulate of atrial action potential APs under Control and the Hcy conditions 
respectively.  
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3.3 Results of multi-scale simulations of the Homocystein 
hormone 
 
The simulated APs and current traces of altered ionic currents under Control, Hcy (50 
µmol/L), and Hcy (500 µmol/L) conditions at a PCL of 1000 ms are show in Figure 3.1A. 
Elevated levels of Hcy are observed to alter the morphology of the AP substantially. These 
changes included an elevated plateau potential during the early stage of repolarisation and 
a more hyperpolarized resting potential. In addition, both APD90 and APD50 were reduced 
from the Control condition of 314.2 ms and 210.6 ms respectively. APD90 was reduced 
under Hcy (50 µmol/L) conditions by 8.3% (287.9 ms) and by 9.2% (261.4 ms) in the Hcy 
(500 µmol/L) case. APD50 was measured to be reduced by 5.3% (199.4 ms) in the Hcy (50 
µmol/L) case and by 16.8% (196.6 ms) under Hcy (50 µmol/L) conditions. The alterations 
in the AP morphology can be attributable to the integrative actions of the Hcy-induced 
electrical remodelling of the Ito (Figure 3.1B), IK1 (Figure 3.1C) and IK,ur (Figure 3.1D). As 
Hcy decreases Ito, which is responsible for the early stage of repolarisation, the AP’s 
plateau potential is elevated. Although the maximal channel conductance of IK,ur is 
reduced, IK,ur is actually increased in the early phase of repolarisation due to this elevated 
plateau potential. However, it decreases in successive repolarisation phases. Augmented 
IK1 contributes mainly to a more hyperpolarized resting potential and an abbreviated APD.  
 
 
 
Table 3.1 
Conductance Gains for Potassium Channels due to Hcy 
Model gto gKur gK1 
50µmol/L 24.8% ↓ 10% ↓ 10% ↑ 
500µmol/L 38.4% ↓ 29.6% ↓ 39.2% ↑ 
. 
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Figure 3.1. Time traces of simulates APs and some of the re-modeled ionic currents under Control 
(red lines), 50 µmol/L Hcy (green lines) and 500 µmol/L Hcy (blue lines) conditions. A. AP profile 
B. Ito. C. IK1 D. IK,ur. Increased Hcy concentration results in APD50 and APD90 abbreviation, a 
hyperpolarized resting potential, and elevated plateau-potentials in the early repolarisation phase. 
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Figure 3.2. Computed APD90 (A), APD50 (B), ERP (C), and CV (D) restitution curves under 
Control (blue line), 50 µmol/L (green line) and 500 µmol/L (red line) conditions. APDr,50 shows 
that APD50 is shortened by Hcy at low excitation rates, but prolonged by Hcy at high excitation 
rates. APDr,90 shows that APD90 is consistently abbreviated due to elevated levels of the Hcy 
hormone. Shift of the ERPr curve left-ward indicates the loss of rate-dependent accommodation of 
ERP, which is pro-arrhythmic. Hcy reduces atrial tissue’s excitability resulting in slowed intra-
atrial conduction. Shift of the CVr curve left-ward indicates that Hcy facilitates atrial tissue to 
conduct high rate excitation waves.  
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The effects of the Hcy hormone on APD are rate dependent. APD90 (APDr,90) restitution 
and APD50 restitution (APDr,50) curves are shown in Figure 3.2A and 3.2B respectively. 
APDr,50 curves show at low excitation rates (large DIs), APD50 is shortened modestly due 
to elevated levels of Hcy. Conversely at high pacing (short DIs), APD50 is observed to 
increase. However, the APDr,90 curves show that elevated levels of Hcy abbreviates 
APD90 consistently for both high and low excitation rates. For both the APDr,50 and 
APDr,90 curves, Hcy flattens them and shifts them left-ward, indicating the loss of rate 
dependent accommodation of APD, similar to the functional impacts of chronic AF-
induced electrical remodelling on human atrial action potentials (Kharche and Zhang 
2008). In addition, it was found that a simple estimation of maximal slopes did not 
necessarily predict the behavior of re-entrant waves in spatial models.  
 
Effects of Hcy on the ERP are shown in Figure 3.2C. Under Control conditions the 
measured ERP was found to be 327.9 ms. Under Hcy conditions, the measured ERP 
decreases by 9.7% to 302.9 ms for 50 µmol/L Hcy and by 16.8% to 273.7 ms for 500 
µmol/L Hcy at a PCL of 1000 ms. Hcy is observed to result in a left-ward shift and flatten 
the ERP restitution curves, indicating the loss of the rate dependent accommodation of 
ERP, similar to the observation of human atrial cells due to AF-induced electrical 
remodelling. 
 
The CV restitution curves shown in figure 3.2D show that under Control conditions and at 
a PCL of 1000 ms the CV is measured to be 0.27 mm/ms. Elevated levels of Hcy cause a 
slowing of the wave propagation to 0.26 mm/ms and 0.25 mm/ms for 50 µmol/L and 500 
µmol/L of Hcy respectively. The reduction of CV may be explained by the role of elevated 
IK1 currents resulting in a hyperpolarisation of the resting potential of the atrial cell. This 
decreases the excitability of the tissue which manifests as a reduction in the intra-atrial 
excitation wave conduction. The effect of Hcy hormone on intra-atrial conduction velocity 
is also rate-dependent. At low excitation rates (i.e. large PCLs), Hcy decreases CV due to 
reduced atrial tissue excitability as a consequence of a more hyperpolarized resting 
potential. As Hcy hyperpolarizes the resting potential to a more negative voltage range, it 
requires more stimulus current to depolarize the cell membrane potential from its resting 
state to the excitation threshold potential of the cell (normally determined by the activation 
potential of the sodium channel, ~ -65 mV), and so the tissue’s excitability will decrease. 
However, at high excitation rate (i.e., small PCLs), Hcy increases CV due to the reduced 
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APD and ERP, which allows tissue to recover sooner from previous excitation. The TVW 
was calculated to study how Hcy alters the tissue’s ability to produce uni-directional 
conduction block by applying a premature stimulus to the refractory tail of a previous 
excitation wave. Hcy moderately reduces the measured VW, which decreases from 14.6 
ms under Control condition to 14.2 ms under Hcy 50µmol/L and 12.9 ms under Hcy 
500µmol/L. Hcy increases the stability of reentrant excitation wave as shown in Figure 3.3, 
in which snapshots of the 3D simulations are shown for Control and Hcy (500 µmol/L) 
conditions. Under the Control condition, the scroll wave is unstable with its organization 
centre (i.e. filament) meandering in a large area of tissue. The scroll wave is non-
sustainable as it self-terminates at approximately 4.2 s. This self-termination is due to a 
combination of factors such as longer wavelength (i.e. larger ERP and higher CV) and the 
fact that they are non-stationary, meaning they do not allow the atria to accommodate the 
re-entrant excitation wave. However, under the Hcy condition (500 µmol/L), the simulated 
scroll wave sustains through the whole period of simulation (6 s). The increased 
persistence of reentrant excitation wave under Hcy condition is attributable to the 
shortened wavelength of excitation waves, as a result of abbreviated ERP and reduced CV.  
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Figure. 3.3. Snapshots of re-entrant waves in a 3D anatomical model of human atria under Control 
(rows a, c, and e) and Hcy 500µmol/L (rows b, d, and f) (ii). Under Control conditions, scroll wave 
self-terminates at 4.1 s and in the presence of Hey the scroll wave persists for the full period of the 
simulation (6 s).  
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Table 3.2 Summary of quantitative results for Control, 50 µmol/L, and 500 µmol/L conditions 
Model Quantity Control 50 µmol/L 500 µmol/L 
Resting potential 
(mV) 
-80.80 -80.4 -82.5 
APD50 (ms) 210.6 199.4 196.6 
APD90 (ms) 314.2 287.9 261.4 
dV/dtmax (mV/ms) 217.10 218.2 202.6 
APDr maximal 
slope 
1.3 1.38 1.45 
Cell 
ERP (ms) 
(stimulus interval 
~ 1 s) 
327.9 302.9 273.7 
CV (mm/ms) 0.27 0.26 0.25 
VW (ms) 14.6 14.2 12.9 1D 
Wavelength (mm) 81.7 74.9 65.4 
3D LS (s) 4.2 N/A >6 
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3.4 Conclusions and discussion of the effects of the Homocystein 
hormone 
 
The study into the underlying mechanisms which result in the onset and maintenance of 
AF has been attributed to numerous risk factors which include ageing, heart disease-
induced electrical and structural remodelling, and gene mutations. While these have been 
extensively studied clinically and experimentally, little knowledge has been obtained about 
the role of abnormal secretion of hormones. In this chapter, the functional role of elevated 
Hcy on atrial excitation was investigated using biophysically detailed computer models 
and multi-scale simulations were performed to evaluate the effects of Hcy-induced changes 
in potassium currents on the electrical activity of human atrium at single cell, 1D strand of 
tissue, and 3D anatomical models.  
 
3.4.1 Main findings 
 
Simulations show that the Hcy-induced electrical remodelling of Ito, IKur and IK1 currents 
have marked effects on the electrical activities of human atrial cells thereby affecting 
excitation wave propagation. The pro-arrythmogenic effects of an elevated Hcy are 
obvious with the reduction in action potential duration, effective refractory period and 
intra-atrial conduction velocity, and the loss of their rate dependency. The integrative 
action of these cellular and tissue properties reduces the wavelength of atrial excitation 
waves allowing atria to sustain high rate re-entrant excitation waves. This pro-arrhythmic 
mechanism is similar to that of AF-induced electrical remodelling on some ion channels 
(Workman, Kane et al. 2001; Zhang, Garratt et al. 2005; Kharche, Seemann et al. 2007) 
and gain-in-function of IK1 arising from KCNJ2 gene mutation. This study substantiates the 
link between an elevated Hcy concentration and incidence of AF in some patients. 
3.4.2 Limitations of the study 
 
While simulations performed on the 3D anatomical structure indicated that elevated levels 
of the Hcy hormone resulted in re-entry, 2D simulations failed to initiate a stable spiral 
wave despite several single cell simulations measurements indicating increased risk of AF 
genesis. This suggests that the 3D structure of atria is an important factor in the genesis of 
AF. The 3D simulations assume that the atria consist of a single cell type. In reality the 
atria is constructed of multiple cell types with differing electrophysiological properties 
which may hinder or exacerbate the genesis of AF (Seemann, Hoper et al. 2006). 
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More recent experimental studies have identified that elevated levels of Hcy alter the 
electrophysiological properties of the sodium channel INa, which is primarily responsible 
for the depolarization of the cardiac myocytes (Cai, Shan et al. 2009). Alterations to the 
ionic current conductance and kinetics of this channel are likely to have a significant 
impact on CV. This may in turn alter the wavelength of which the tissue can sustain re-
entrant waves. The combined effects of this re-modelling in conjunction with the 
alterations to the potassium currents require further simulation. 
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Chapter 4 
A computational evaluation of the arrhythmogenic effects 
of Serotonin in the human atria 
 
4.1 Introduction to serotonin 
 
Previous chapters of this thesis have shown studies into how genetic defects and hormonal 
imbalances can result in an alteration of ion channel properties causing a change to the 
overall electrophysical behaviour of the cell, thereby increasing the susceptibility of the 
tissue to the genesis and maintenance of AF. However, understanding the mechanisms by 
which different hormones alter the electrophysiology of atrial myocytes may provide 
valuable insight into possible drug development strategies which may aid clinical treatment 
of AF.  
 
Elevated levels of 5-hydroxytryptamine (5HT), more commonly known as Serotonin, has 
long been observed to produce strange electrical properties in the atrium (Hollander, 
Michelson et al. 1957; Lemessurier, Schwartz et al. 1959). However, as 5HT receptors 
have been identified in multiple systems which regulate the heart rate it has not yet been 
conclusively identified how elevated levels of 5HT effect the arrhythmogenic properties of 
atrial cells. The 5HT receptor 5-HT4 was identified in the right atrium (Yusuf, Al-Saady et 
al. 2003) which provides the  mechanism by which 5HT could bind to the ion channel 
protein responsible for the ICaL current and alter the electrophysiology of the cell directly. 
Interestingly, this receptor is found in the atrium, but is absent in the ventricles (Yusuf, Al-
Saady et al. 2003). This selectivity of the 5HT hormone to act on the atria could provide a 
novel mechanism by which medication could be used to specifically target the atria. 
 
This chapter studies how changes in the L-type calcium current (ICaL) resulting from non-
physiological levels of the hormone 5HT affects the tissues’ susceptibility to AF. The 
effects of 5HT on ICaL current densities have been quantified experimentally (Pau, 
Workman et al. 2007). These results are incorporated into a detailed electrophysiological 
model of the human atrium. Theses simulated cells are investigated at single cell, 1D 
strand, 2D sheet and full 3D anatomical geometry, and the results are used to quantify the 
arrhythmogenic effects of 5HT. 
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4.2 Methods 
 
This section outlines the development of four cell types: sinus-rhythm (SR), elevated  
levels of 5HT  in a cell under normal SR (5HT), cells with reduced ICaL current density due 
to AFER  (AF), and AF cells with elevated levels 5HT (AF+5HT). The multi-scale 
simulations as describe in Chapter One are implemented to quantify the arrhythmogenic 
effects of alterations to the current density of  ICaL. 
4.2.1 Simulating the effects of 5HT 
 
A CRN biophysically detailed 21-variable cell model for simulating the human atrial AP 
was implemented in this study (Courtemanche, Ramirez et al. 1998). The ICaL current 
responsible for the flow of Ca
2+
 ions across the cell membrane was observed 
experimentally to be increased by elevated levels of the 5HT hormone and AFER 
(Workman, Kane et al. 2001; Pau, Workman et al. 2007). The mathematical interpretation 
of the ICaL ion-channel is described by the following Hodgkin-Huxley formulation in the 
CRN model: 
)(,, CaLCaLCaLCa EVffdgI −××=                                       (4.1) 
where gCaL is the current conductance (0.1238 nS/pF), ECaL  is the reversal potential of ICaL 
(-65 mV), d is the activation gate, f is the inactivation gate, and fCa in the [Ca
2+
]i dependent 
inactivation gate.  
Alterations due to elevated 5HT and AFER are modelled as an alteration in the 
conductance gCaL and are based on Workman et al. (Pau, Workman et al. 2007) where 
experiments were performed on isolated atrial cells. The study concluded that the 
alterations to gCaL under 5HT conditions result in a 288.7% increase, AF in a 43.8 % 
reduction, and AF+5HT in a 20.2% increase. These alterations are also outlined in Table 
4.1. 
Table 4.1 Conductance Alterations to ICaL Channels due to 5HT and 4F 
Model gCaL 
5HT 288.7% ↑ 
AF 43.8% ↓ 
AF+5HY 20.2% ↑ 
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4.3 Results 
 
The aforementioned methods were implemented to quantify the arrhythmogenic effects of 
5HT, AF, and AF+5HT on the cellular, 1D, 2D, and anatomical 3D level. A summary of 
the measured quantities are listed in Table 4.2. 
4.3.1 Effects of 5HT, AF, AF+5HT on single atrial myocyte 
 
Simulated AP profiles and ICaL current a trace at PCLs of 1000 ms, 430 ms and 330 ms 
under SR, 5HT, AF, and AF+5HT conditions are shown in Figure 4.1. At a PCL of 1000 
ms the APD90 of the SR case is measured to be 314.2 ms. When 5HT is present ICaL current 
is augmented substantially and the APD90 is increased by 19.7% to 376.7 ms. Under AF 
conditions ICaL current is reduced causing a shortening of APD90 by 16.0% to 263.9 ms. In 
the AF+5HT case ICaL is augmented from SR conditions, resulting in an increased APD90 
of  7.8% to 338.8 ms. At a PCL of 430 ms the SR case has and APD90 of 274.9 ms. Under 
5HT conditions the APD90 is increased by 10% to 302.6 ms, where in the AF case APD90 
is reduced by 17.3% to 227.1 ms. In the AF+5HT case the APD90 is reduced by 6.2% to 
257.9 ms. At a PCL of 340 ms the SR case has an APD90 of 237.7 ms. Under 5HT 
conditions the APD90 is increased by 16.6% to 277.2 ms, where in the AF case the APD90 
is reduced by 10.2% to 213.3 ms. In the AF+5HT case the APD90 is reduced by 18.4% to 
193.9 ms. Interestingly at lower PCLs 5HT had the effect of increasing APD90 from SR 
conditions and decreasing APD90 from SR conditions at high PCLs. This indicates that the 
cardio-protective effects of the 5HT hormone are limited to low pacing rates and at high 
pacing 5HT results in an increased risk of AF. Upstroke velocity in the SR case was 
measured at 217.1 mV/ms. The 5HT case resulted in a reduction of 2.5% to 211.8 mV/ms. 
Under AF conditions the upstroke velocity is increased moderately by 0.5% to 218.3 
mV/ms. In the AF+5HT case the maximal upstroke velocity was reduced from the AF case 
but was still 0.05% lower than the SR case, with an upstroke velocity of 216.1 mV/ms. As 
ICaL current is nominal in the upstroke part of the AP the alterations in maximal slope are 
likely a result of the alteration to the RP. 
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4.3.2 The effects of HT5 on APR, ERP, and CV restitution curves 
 
The APDr,90 curves in Figure 4.2A shows that in the 5HT and AF cases there was a 
marked increase and decrease respectfully in APD90 in comparison to SR over the full 
range of DIs. The AF+5HT restitution curve showed some interesting characteristics: at 
long DI the APD90 remained approximately 25 ms longer than the SR case. However, as 
DI is reduced to less than 235 ms the difference in APD90 between the SR and AF+5HT 
case begins to reduce until at very short DI (~20 ms) they are equal to the SR case. This 
indicated that any possible anti-arrhythmogenic effects of 5HT are reduced in a high 
pacing regime. The APDr,50 curves were also constructed and are shown in Figure 4.2B 
and shows similar structural characteristics to the APDr,90 curves. 
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Table 4.2 Summary of quantitative results for SR, 5-HT,  AF and AF+5HT conditions 
Model Quantity SR 5HT AF AF+5HT 
Resting potential 
(mV) 
-80.8 -79.2 -81.3 -80.5 
APD90 (ms) 314.2 376.7 263.9 338.8 
Overshoot (mV) 24.7 25.4 24.6 24.8 
dV/dtmax (mV/ms) 217.1 211.8 218.3 216.1 
APDr maximal slope 1.3 1.75 0.93 1.51 
Cell 
ERP (ms) (stimulus 
interval ~ 1 s) 
327.9 396.2 275.3 354.5 
 Cut off BCL (ms) 328.7 360.4 298.7 339.0 
CV (mm/ms) 0.26 0.27 0.25 0.26 
Cut off S2 (ms) 320 380 315 345 
VW (ms) 14.6 9.3 17.9 10.1 
 
Wavelength (mm) 81.7 101.7 66.0 87.8 
LS (s) 1.4 1.1 1.8 0.9 
DF (Hz) 3.6 1.5 5.2 0.6 2D 
MS (mm) 49.2 72.0 17.4 58.0 
LS (s) 4.2 < 1 > 6 4.5 
3D 
DF (Hz) 3.1 N/A 4.2 2.7 
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Figure 4.1 Simulated AP profiles (left column) and ICaL current traces (right column) using the 
CRN model models under SR (blue lines), 5HT (green lines), AF (red lines), and AF+5HT (purple 
lines) conditions at PCLs of. A: 1000 ms. B: 430 ms. C: 340 ms. 
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The ERPr curves given in Figure 4.2C show that at a PCL of 1000 ms under SR conditions 
the ERP is measured to be 327.9 ms. Under 5HT conditions the ERP is increased 
substantially by 20.8% to 396.2 ms and in contrast AF reduces ERP by 16% to 275.3 ms. 
Under AF+5HT conditions the ERP is measured to increase moderately by 8.1% to 354.5 
ms. These results indicate that at low pacing rates AF reduces ERP resulting in an 
increased susceptibility to arrhythmogenesis whereas in the AF+5HT case ERP is restored 
to values modestly higher than the SR case indicating possible arrhythmogenic effects of 
5HT. It is also observed that in a high pacing regime under 5HT and AF conditions the 
ERPr curves are flattened, indicating a loss of rate dependant adaptation.  In the AF+5HT 
case the ERP, which is consistently higher than SR at low pacing rates, has a dramatic 
increase in slope at high pacing rates, reducing ERP to values lower than SR. The cut-off 
PCL under SR conditions was recorded to be 328.7 ms, and under 5HT conditions this 
increased by 9.63% to 360.4 ms. For AF conditions the cut-off PCL is reduced by 8.79% to 
298.7 ms and for AF+5HT conditions the cut-off PCL is 339.0 ms, which is 3.16% higher 
than the SR case. This further indicates the restorative effects of the 5HT hormone, while 
AF results in a negative shift, demonstrating an increased ability of atrial cells to sustain 
high-rate electrical excitation rates. 
 
The CVr curves are shown in Figure 3D. At a PCL of 1000 ms the measured CV under SR 
conditions was 0.26 mm/ms. In the 5HT case the CV is increased modestly to 0.27 mm/ms, 
and the AF case results in a modest reduction to 0.25 mm/ms. Measured CV under 
AF+5HT conditions was restored to 0.26 mm/ms. These results again indicate the 
restorative effects of 5HT in a low pacing regime. The cut-off PCL for the SR case was 
measured to be 320 ms. Under 5HT conditions there is a shift in the positive direction, with 
a cut-off PCL of 380 ms. In contrast, AF results in a negative shift of the restitution curve 
with a measured cut-off PCL of 315 ms. The AF+5HT case causes a positive shift from SR 
conditions, with a measured cut-off PCL of 345 ms. A positive shift in the CVr curve 
indicates a loss of propagation in a high pacing regime whereas, for example, the AF case 
there was a negative shift which indicates successful wave propagation is possible in a high 
pacing regime. It is observed that in the AF+5HT case the restitution curve is shifted back 
to a position which is more similar to that of SR conditions, indicating that the hormone 
5HT counteracts the arrhythmogenic effects of AF. 
 
The wavelength at which the tissue can sustain re-entry is calculated as the product of the 
CV and APD90. Under SR conditions the wavelength is calculated to be 81.7 mm, and for 
5HT conditions the wavelength is increased to 101.7 mm.  In the AF case there is a 
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significant reduction to 66.0 mm. This is restored to 87.8 mm in the AF+5HT case 
showing the possible anti-arrhythmogenic effects of 5HT.  
 
4.3.3 Effects of 5HT on the temporal and spatial vulnerability window 
 
The TVW was calculated using the 1D strand of tissue and is shown in Figure 4.2F. Under 
SR conditions the TVW was measured to be 14.6 ms, whereas under 5HT conditions the 
VW was reduced by 36.3% to 9.3 ms. In the AF case the TVW is increased by 22% to 17.9 
ms and in the AF+5HT case the TVW is reduced by 30.8% to 10.1 ms. The 5HT hormone 
has the effect of dramatically reducing the TVW resulting in a cardio-protective effect.  
 
The SVW was calculated by applying a stimulus to an idealised 2D homogenous sheet is 
shown in Figure 4.2F. In the SR case the SVW required to initiate re-entry was measured 
to be 49.2 mm. Under 5HT conditions the SVW required is increased by 42% to 72.0 mm. 
Under AF conditions the SVW is reduced dramatically by 64.6% to 17.4 mm. In the 
AF+5HT case the SVW is measured at 58.0 mm, which is 17.8% longer than under SR 
conditions. These results again indicate that the effects of 5HT are cardio-protective in 
cells which have undergone AF. 
 
 
4.3.4 Simulation re-entry in a homogenous 2D sheet of atrial tissue. 
2D simulations of re-entry in a homogenous sheet of atrial tissue are shown in Figure 4.3 
and an accompanying core trace of the spiral tip, a representative time-voltage plot of a 
single atrial cell, and power spectrum density plot are shown in Figure 4.4. In SR 
conditions the LS of the resultant spiral wave is 1.4 s with a DF of 3.6 Hz. In the 5HT case 
the LS is reduced substantially due to the increased APD and ERPr. AF conditions result in 
a moderately prolonged LS of 1.8 s and a increase in DF to 5.2 Hz. The AF+5HT case 
causes a shortening of LS to 0.9 and a dramatic reduction of DF to 0.6 Hz. 
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Figure 4.2 Simulated APDr,90, APDr,50 , ERPr, CVr, Temporal VW, and  Spatial VW    
calculated using the CRN model under SR (blue), 5HT (green), AF (red), and AF+5HT (purple) 
conditions. A: APDr,90 curves. Bi: APDr,50 curves. Ci: ERPr curves. D: CVr curves. E: Temporal 
VW. F: Minimal substrate.  
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Figure 4.3 Simulation of 2D re-entry in an idealized sheet of virtual atrial tissue under SR, 5HT, 
AF, and AF+5HT conditions. Panels show 3 s of simulation starting from 0 ms in the top left panel 
progressing in 100 ms intervals horizontally from left to right until the bottom right panel. 
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Figure 4.4 2D spiral wave tip traces (panel i), representative AP traces taken from 2D simulations 
(panel ii), and power spectrum density showing frequencies of maximal power (panel iii) under SR 
(A), 5HT (B), AF (C), AF+5HT (D) conditions. 
  
 
 
 
 88 
4.3.5 3D Simulation of a detailed anatomical correct construct of 
the atria 
 
The simulation of spiral wave behaviour in a realistic 3D geometry is show in Figure 4.5 
and a representative time-series plot of a selected node in the atrial wall along with a power 
spectrum density plot to indicate the dominant frequency is shown in Figure 4.6. Under SR 
conditions the re-entrant wave behaviour dies after 4.2 s and has a DF of 3.1 Hz. In the 
5HT case, due to the long APD90 and an increase in ERP, the 3D construction is unable to 
maintain a persistent spiral wave. In the AF case a persistent stable spiral rotor is born for 
the duration of the simulation. The DF of the waves is measured to be 4.2 Hz. Under 
AF+5HT conditions the re-entry persists for only 0.3 ms longer than in SR conditions and 
the DF is reduced to below SR conditions to 2.7 Hz. The fact that oscillations persisted in 
the 3D case and not in the 2D simulation is an indication that anatomical structure is 
important in the onset of AF. 
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Figure 4.5 Simulation of re-entry in a 3D geometry of the human atria under SR, AF, and AF+5HT 
conditions. Panels show 4s of simulation starting from 0 ms in the top left panel progressing at 200 
ms from left to right in 200 ms intervals until bottom right panel 
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Figure 4.6 AP traces taken from 3D simulations (panel i), and power spectrum density showing 
frequencies of maximal power (panel ii) under SR (A), 5HT (B), AF (C), AF+5HT (D) conditions. 
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4.4. Conclusions and discussion 
 
This section outlines the main findings of this chapter. There is also a discussion into the 
limitations of the study, in particular the modelling methods for simulating AFER and the 
simulation of the ICaL current in the CRN model. The results are also compared to that of 
previous simulation studies and the possible implications in the clinical setting are 
discussed. 
 
4.4.1 Main findings 
 
It has been known for some time that elevated levels of 5HT is linked to an increase in 
susceptibility to AF, primarily by increasing the atrial myocytes’ susceptibility to 
exhibiting EADs and DADs (Kaumann and Levy 2006). Clinical evidence indicates that 
5HT directly alters the conductance of ICaL (Pau, Workman et al. 2003). However, the 
possible anti-fibrillatory effect of 5HT when applied to tissue which has undergone AFER 
has not been studied. The main focus of this chapter was therefore to investigate the  
arrhythmogenic effects of 5HT. We employed computational techniques to simulate the 
effects of this hormone by incorporating experimental data into a biophysically detailed 
model and studying the effects of the hormone on multi-scalar tissue levels. AFER was 
simulated in this study as a reduction in the ICaL, which when incorporated into single cell 
model simulations resulted in a substantially reduced APD and ERP. Simulations in an 
idealised 2D sheet indicated that the reduction to ICaL was insufficient to allow the tissue to 
maintain re-entry. However, in the 3D construct of the atria the reduction in ERP was 
sufficient to allow the initiation and maintenance of stable spiral waves. The increase in 
ICaL due to elevations in 5HT is observed to limit the effects of AFER via the restoration of 
ICaL current density to values more comparable to those observed under SR conditions. In 
fact, APD and ERP are seen to be slightly augmented in comparison to SR conditions and 
as a result the 3D atrial tissue simulations are no longer able to sustain re-entrant 
behaviour. Our principal findings were therefore that the 5HT hormone augmented the ICaL 
current sufficiently in tissue which had undergone AFER to provide a cardio protective 
effect. Therefore it can be concluded that targeting the 5-HT4 receptors in tissue which has 
undergone AFER may provide a possible target for the development of drug treatments. 
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4.4.2 Limitations of the study 
 
The potential limitations of the model used in this study have been discussed previously 
(Courtemanche, Ramirez et al. 1998; Cherry and Evans 2008). A limitation of our 3D 
simulations is the absence of heterogeneity in the structure of the atria, both electrically as 
the structure only consists of atrial cell types while it is known that cells in different 
regions of the atria have different electro-physical properties (Seemann, Hoper et al. 2006). 
The model also neglects spatial heterogeneity due to fibers within the atria.  
 
Our simulations show that elevated levels of 5HT were found to have a cardio protective 
effect when applied in conjunction with cells that have undergone AFER as a result of 
prolonged periods of rapid pacing due to AF. However, elevated 5HT levels under normal 
SR produced an AP which has an abnormally large dome in phase III of the repolarisation , 
substantially prolonged APD90, which is not consistent with experimental data. In the CRN 
model this resulted in a substantially extended simulated ERP which severely limited the 
tissues’ susceptibility to sustain re-entrant waves, resulting in rapid break up of any re-
entrant behaviour in our simulations. In clinical reality it is observed that elevated levels of 
5HT under normal SR results in spontaneous DADs and EADs. However, no such 
phenomena were observed. The absence of this phenomenon is thought to be due to the 
underlying biology on which the CRN model is based. In fact currently no atrial cell model 
had been observed to produce them. However, it is possible to artificially test the tissues’ 
susceptibility to eliciting a spontaneous depolarization by artificially incorporating a 
sudden release of Ca
2+
 from the SR (Priebe and Beuckelmann 1998).  
 
In addition to the simulations failing to successfully reproduce DADs and EADs, the 
methods used to simulate the effects of AFER were simplistically modeled as a reduction 
in ICaL current density. This neglects the several other ion-channels know to be remodeled 
during AFER. In addition alteration in the time kinetics in ICaL, which are know be altered 
by elevated levels of 5HT, are neglected. It is observed that modelling the effects of AFER 
using this method was sufficient to induce re-entry in a 3D geometry. However, 
experimental evidence has shown that multiple ion-channels are observed to be remodeled 
as a result of prolonged rapid pacing. Figure 4.7Ai and 4.7Aii show simulated APs which 
incorporate more detailed physiological changes to ion channels as described by Workman 
et al. (Workman, Kane et al. 2001). In addition to this we also tested the tissues’ ability to 
initiate a spontaneous depolariastion as described by Priebe et. al. (Priebe and 
Beuckelmann 1998), which can be seen in Figure 4.7Bi and 4.7Bii. In this method an 
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injection of Ca
+
  ions are placed into the cell 1 s after the previous excitation. This may 
initiate a release of Ca
+
 from the SR causing an AP to be elicited. It is observed that under 
normal SR conditions the tissue is unable to elicit a sudden depolarisation. However, under 
SR+5HT conditions, a sudden depolarisation is possible. This result confers well with 
experimental observations where healthy extracted atrial cells exhibit EADs and DADs 
when subjected to increased concentrations of 5HT (Pau, Workman et al. 2007). In 
addition, experimental evidence shows that atrial cells from patients who are suffering 
from persistent AF show no spontaneous depolarisations even if there are elevated levels 
of 5HT. 
 
4.4.3 Clinical significance and comparison to previous studies 
 
In healthy tissue extracted from a patient in SR the hormone 5HT augments ICaL resulting 
in EADs and DADs which are extremely dangerous as resultant ectopic beats act as focal 
points for the initiation of arrhythmias. However, in patients who have undergone AFER 
due to persistent AF the effects of the hormone is to increase the ICaL which results in an 
increase in APD and ERP providing a possible cardio-protective effect. Current 
pharmacological treatment methods are based on the management of AF by rate and 
rhythm control However, the success rates of commonly used drugs have been 
disappointing with high rates of reoccurrence of the underlying arrhythmia (Lally, Gnall et 
al. 2007). The naturally occurring 5HT hormone acts as an agonist for the 5HT4 receptor 
which is located only in the atrial tissue, therefore providing an attractive target for drug 
development.  It has recently been shown that a specific antagonist, RS-10032, suppressed 
AF in a porcine model. A second 5HT4 receptor antagonist, piboserod was also in clinical 
development but was halted for unspecified reasons (Rahme, Cotter et al. 1999; Page and 
Roden 2005). 
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Figure 4.7 A: Simulated APs and B: Simulated AP initiated at 10 s followed by an artificially 
induced spontaneous depolarisation via the injection of Ca+ into the cell at 11 s. The CRN model 
was used for simulations and cases, SR (blue lines), 5HT (green lines), AF (red lines), and 
AF+5HT (purple lines) are shown. 
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Chapter 5 
Computational evaluation of electrophysiological effects 
of Beta-Blockers on chronic atrial fibrillation 
 
5.1. Introduction to Beta-Blockers 
 
Cardiac modelling can provide valuable insights into how alterations in the properties of 
ion-channels as a result of various medical conditions can manifest themselves as the 
genesis and maintenance of AF. However, these models can also be utilised to simulate the 
effectiveness of current pharmacological treatment methods. These methods are favored by 
clinicians in the management of AF as they are non-invasive and far simpler to administer 
than surgical counterparts. The emphasis on anti-arrhythmic drugs is reflected in recent 
experimental and clinical studies (Workman, Kane et al. 2003; Wettwer, Hala et al. 2004; 
Ehrlich, Nattel et al. 2007; Shamiss, Khaykin et al. 2009; Viswanathan and Page 2009; 
Workman 2009). The underlying mechanism by which these drug actions are effective is 
the modification of the electrophysiological properties the atrial myocyte that are anti-
arrhythmogenic. Despite the significant advances in ablation and cardioversion techniques 
(Schouchoff 2007; Buch and Shivkumar 2009; Callahan, Di Biase et al. 2009; Saltman and 
Gillinov 2009; Smelley and Knight 2009; Weerasooriya, Jais et al. 2009), anti-arrhythmic 
drugs remain the first course of action for management of AF (Wijffels and Crijns 2004; 
Amani and Smith 2005; Olshansky 2005; Roy, Talajic et al. 2008; Kalus 2009). Various 
pharmacological agents have been used traditionally and have been improved considerably 
in their function (Viswanathan and Page 2009). 
 
A large proportion of pharmacological intervention relies on atrial-specific ion channel 
augmentation, or blocking drugs (Burashnikov and Antzelevitch 2009), and are commonly 
used for reducing aberrant atrial electrical activity. In particular, members of the class of 
drugs called beta-blockers (BBs), also called beta-adrenergic antagonists, are used as a 
preventative treatment for elevated blood pressure. The effectiveness of BBs was 
recognized in the early 1960s and BBs were judged to satisfactorily control atrial 
arrhythmias (Fitzgerald 1975). The effects of some BBs extend to atrial cells and may 
facilitate sinus rhythm in AF patients (Singh 2009). The effectiveness of individual 
members of this class of drugs has been studied in expansive clinical trials (Steeds, 
Birchall et al. 1999; Kuhlkamp, Schirdewan et al. 2000; Plewan, Lehmann et al. 2001). 
BBs target the catecholamine secreting cardiac adrenergic system, over activity of which 
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initiates and maintains AF (Bettoni and Zimmermann 2002; Gould, Yii et al. 2006). The 
antiarrhythmic effects of these agents are generally attributed to the reversal of beta-
adrenergic stimulation of cardiac cells. In addition to the adrenergic system, BBs also 
affect dysfunctional atrial ion channels and attempt to restore atrial AP and ERP, in view 
of rhythm control (Wijffels and Crijns 2004; Kalus 2009) and  to educe the incidence of 
persistent re-entrant circuits atypical of AF in the atria.  
 
Recent experimental studies by Workman et al. (Workman, Kane et al. 2001; Workman, 
Kane et al. 2003; Workman 2009) quantified the BB-induced ion channel alterations in 
human atrial myocytes isolated from human patients in sinus rhythm (SR, Control) and 
AFER. However, an experimental evaluation of the isolated effects of BBs on organ level 
re-entrant circuits proved difficult. This study therefore adopts a multi-scale computer 
modelling approach with the aim of quantifying the anti-fibrillatory consequences of BBs 
on atrial conduction propagation behaviour in atrial cell and tissue models. This study 
quantifies the cardio-protective nature of BBs under Control (i.e. sinus rhythm, SR) 
conditions, and also quantifies the degree of restorative effectiveness under AF conditions. 
To address these aims, simulations in cell, 1D, 2D and 3D anatomical models were 
performed under SR, BB, AF, and BB treated AF (AFBB) conditions. 
 
5.2. Methods 
 
This section outlines the techniques used to simulate the effects of BBs and AFER on 
human atrial cells. The alterations to ion-channel dynamics were incorporated into the 
NYG and CRN model, which are two commonly used atrial cell models. A series of 
simulations as descried in Chapter One are performed to quantify the arrhythmogenic 
effects of cells under these conditions. 
5.2.1 Cellular excitation models 
 
The CRN (Courtemanche, Ramirez et al. 1998) and NYG. (Nygren, Fiset et al. 1998) 
(hereafter referred to as NYG) models were used in this study. Although based on similar 
experimental data, the spike-and-dome AP produced by the CRN model and the triangular 
AP produced by the NYG model are strongly regulated by the respective ionic currents and 
biophysical properties considered in the two models. Intracellular ion dynamics are also 
different between the two models, with the NYG model incorporating a cleft space. With 
detailed mathematical descriptions of ionic currents and intracellular ion dynamics, the 
CRN model consists of a 24 variable non-linear coupled ODE system and has been used 
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widely in computational studies (Zhang, Garratt et al. 2005; Seemann, Hoper et al. 2006; 
Kharche, Garratt et al. 2008). The 29 variable ODE NYG model, based on the previous 
LMCG model (Lindblad, Murphey et al. 1996), also consists of biophysically-detailed 
descriptions of cell membrane ion currents and intracellular ion dynamics. The NYG 
model is parametrically tuned for stable APs at a pacing frequency of 1 Hz under basal 
(SR) conditions. It has been used in previous computational studies, and has been shown 
by others to be functionally similar to the CRN model (Zhang, Garratt et al. 2005). 
Conductance parameters in the CRN model can be manipulated to reproduce the NYG 
model AP (Syed, Vigmond et al. 2005).  However, prolonged pacing of the NYG model, 
even at low pacing rates, gave rise to errant spontaneous APs. The pacing protocols in 
simulations using both models were therefore altered to avoid such modelling defects. 
 
Table 5.1 Ion channel conductance for major currents under SR conditions and their percentage 
changes under AF, BB, and AF+BB conditions. 
 gK1 gCaL gto gKur INaK 
SR 0.09 nS/pF 0.1238 nS/pF 0.1652 nS/pF gKur 0.6 nS/pF 
AF 90%  ↑ 64% ↓ 65%  ↓ 12% ↑ 12% ↓ 
BB 8% ↓ 16% ↑ 29% ↓ 14% ↑ - 
AFBB 74.8% ↑ 58% ↓ 75% ↓ 18% ↑ 12% ↓ 
 
5.2.2 Ionic current alterations due to BB and AF on atrial cell APs 
 
The effects of BBs on human atrial-isolated myocytes were taken from an experimental 
study by Workman et al. (Workman, Kane et al. 2003). The experimental data are based 
on voltage clamp studies of enzymatically isolated human atrial cells from atrial 
appendages of a total of 40 patients in SR. BBs were seen to reduce the inward rectifier 
potassium current (IK1) by 8%, with an increase in the L-type calcium current (ICaL) of 
16%, a reduction in the transient outward current (Ito) of 29%, and an increase in the 
sustained outward potassium current (IKsus) of 14%. AF induced ion channel remodelling 
has been quantified in a previous experimental study (Workman, Kane et al. 2001) and was 
studied in depth in our previous computer modelling simulations (Zhang, Garratt et al. 
2005; Kharche, Garratt et al. 2008). In brief, ion current alterations due to AF were found 
to be a 90% increase of the IK1, a 64% reduction of ICa,L, a 65% reduction of Ito, a 12% 
increase of IKsus, and a 12% reduction of the sodium potassium pump (INa,K). The effects of 
BB on AF affected cell models (AFBB) were simulated as a combination of the ion current 
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remodelling as described for AFER and BB above. The alteration of ion currents to 
simulate AF and BB are listed in Table 5.1. Cell level ion channel remodelling due to BB 
and AF was incorporated into the CRN and NYG cell models. 
5.3. Results  
 
The effects of BB, AF and AFBB affected cells and tissues were quantified as described 
above, using cellular, 1D, 2D and 3D models. The multi-scale quantitative cell, 1D, 2D and 
anatomical 3D results are summarised in Table 5.2 for the CRN and NYG models. Please 
note that as previously outlined in Chapter One the 4
th
 AP is taken for measurement in the 
NYG simulations to ensure the stability of the simulations. For consistency the 4
th
 AP is 
also measured in the CRN model, this explains the slight difference in values from the 
standard results outlined in Table 1.1. 
 
5.3.1 Effects of AF, BB and AFBB on single cell atrial APs 
 
The simulated atrial cells APs, as well as some major currents, under the SR, BB, AF, and 
AFBB conditions are shown in Figure 5.1. In the CRN case under the SR condition, the 
measured APD90 is 312.9 ms, with BB prolonging APD90 to 317.4 ms, a modest increase 
of 1.4%. AF dramatically abbreviated APD90 by 53.8% to 147.6 ms. The combined effect 
of AF and BB (i.e. the AFBB case) gave an APD90 of 161.0 ms, a 9.1% increase in 
comparison to the AF case. AF reduced the upstroke dV/dtmax as compared to SR (a 
reduction of 5%). 
 
The effects on NYG model APs were qualitatively similar to that of the CRN model, with 
the APD under the SR being 221.3 ms, and 242.6 ms under BB conditions (an increase of 
9.6%). AF dramatically reduced APD to 110.4 ms (a 50.1% reduction). The AFBB case 
resulted in an AP of 121.8 ms (a 10.3 % increase compared to the AF condition).  The 
upstroke velocity was measured to be 217.1 mV/ms and 141.7 mV/ms for the CRN and 
NYG models respectfully. The application of BB has conflicting results between the two 
models. In the CRN model BB is observed to reduce upstroke velocity modestly by 0.8% 
to 215.3 mV/ms. In contrast, in the NYG model it is increased by 5.7% to 149.8 mV/ms. In 
the AF case upstroke velocity is reduced in both the CRN and NYG models to 205.6 
mV/ms and 139.3 mV/ms respectfully. This indicated that AF results in a possible 
reduction in CV for both models. The application of BB to the AF case (AFBB) results in 
no significant change in the CRN model. However, in the NYG model there is a modest 
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increase of 7.0% to 149.1 mV/ms in comparison to the AF case. This indicates a possible 
restorative effect due to application on BBs 
 
AF results in the reduction of ICaL and augmentation of IK1 which have a significant effect 
on the morphology of the simulated APs. These changes have also been observed 
experimentally by Workman et al. (Workman, Kane et al. 2001) validating the simulations. 
The application of BB results in a minor augmentation of ICaL and a reduction in IK1 
alleviating the effects of AF modestly and therefore providing an anti-arrhythmogenic 
effect. The effects of AF on cellular AP have also been quantified in previous simulation 
studies (Zhang, Garratt et al. 2005; Kharche, Seemann et al. 2007; Kharche and Zhang 
2008). The effects of BB on SR atrial cells have also been studied by Workman et al. 
(Workman, Kane et al. 2003) and our simulations also agree well with this data.  
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Table 5.2 Summary of multi-scale simulations using the CRN and Nygren models. The NYG 
model was found to be unsuitable for prolonged simulations and therefore was not used in the 2D 
and 3D simulations. 
Model Quantity 
SR 
(CRN/  
Nygren) 
BB 
(CRN/  
Nygren) 
AF 
(CRN/  
Nygren) 
AF+BB 
(CRN/  
Nygren) 
Resting potential 
(mV) 
-81.2 / -73.7 -80.5 / -72.9 -83.9 / -77.8 -83.7 / -77.3 
APD90 (ms) 312.9 / 221.3 317.4 / 242.6 147.6 / 110.4 161 / 121.8 
dV/dtmax (mV/ms) 217.1 / 141.7 215.3 / 149.8 205.6 / 139.3 205.1 / 149.1 
APDr maximal 
slope 
1.3 / 0.64 0.95 / 0.7 1.6 / 0.49 1.53 / 0.53 
Cell 
ERP (ms) 
(stimulus interval 
~ 1 s) 
327.9 / 216 338.2 / 289 165.3 / 154 179.8 / 173 
 Cut off BCL (ms) 325 / 200 330 / 225 142 / 125 119 / 125 
CV (mm/ms) 
0.2666 / 
0.2719 
0.2686 / 
0.2666 
0.2553 / 
0.2722 
0.2567 / 
0.2681 
Cut off S2 (ms) 304 / 213 308 / 250 186 / 130 198 / 136 
TVW (ms) 14.6 / 12.1 15.7 / 11.8 13.6 / 8.0 13.2 / 9.1 
1D 
Wavelength (mm) 83.4 / 60.2 85.3 / 64.7 37.7 / 30.1 41.3 / 32.65 
LS (s) 1.4 3.4 > 10 > 10 
DF (Hz) 3..6 < 3 7.6, 16 7.3, 14.2 
Tip meander area 
(cm2) 
5.25 2.04 6.01 1.87 
     2D 
MS (mm) 49.1 / 27.5 60 / 33.5 17.4 / 15 27.5 / 16 
LS (s) 4.2 3.3 > 6 > 6 
     3D 
DF (Hz) 3.1 2.8 7.1 6.5 
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Figure 5.1 Simulated AP profiles and major current traces using the CRN (left column) and NYG 
(right column) models under SR (blue lines), BB (green lines), AF (red lines), and AFBB (purple 
lines) conditions. Ai, Aii: AP profiles. Bi, Bii: ICaL current traces. Ci, Cii: Ito current traces. Di, Dii: 
IKur current traces. Ei, Eii: INaK current traces. Fi, Fii: IKr current traces. 
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5.3.2 APD and ERP restitutions under SR, BB, AF, and AFBB 
conditions 
 
APDr using the CRN and NYG models are shown in Figure 5.2, Ai and Aii respectfully. 
APDr were studied in a wide DI range to allow the study of rate dependent pacing at high 
and low rates. Both models gave a consistently higher APD across the range of pacing 
rates under BB conditions as compared to the SR case. The AF case, on the other hand, 
gave consistently lower APD than SR across the range of pacing rates. The effects of BB 
on SR and AF affected cell models was to augment APD marginally across the range of 
pacing rates.  
 
The APDr maximal slopes gave different results in the two models (Figure 5.2, Ci and Cii). 
Under SR conditions, the maximal slopes of APDr using CRN model was 1.3 whilst that 
using the NYG model was 0.64. The maximal slope of APDr under BB conditions was 
reduced in the CRN model by 26% and increased in the NYG model by 9.4%. Under AF 
conditions, the CRN model gave an increased APDr maximal slope (by 23.5%) whilst the 
NYG model gave a reduced slope (by 23.4%). Under AFBB conditions, APDr maximal 
slope was augmented in the CRN model by 17.6% and reduced in the NYG model 17.1%. 
 
The alterations in maximal APDr slope under ion current remodelled conditions using the 
CRN model are due to the large changes in the repolarising and depolarising currents and 
depends on the quantitative change in the functional role of these currents during APs.  
Such alterations in APDr maximal slopes have been seen in our previous computational 
studies (Zhang, Garratt et al. 2005; Kharche, Seemann et al. 2007; Kharche, Garratt et al. 
2008; Kharche, Seemann et al. 2008; Zhang, Garratt et al. 2009). The NYG model is, 
however, fine tuned for reproducing human atrial AP at 1 Hz and may not be as robust as 
the CRN model after a few excitations at any pacing rate. The underlying ionic 
mechanisms regulating the APs in the CRN and NYG models are different, which accounts 
for the difference in APDr properties of the two models under similar alterations of ionic 
channels (Jacquemet 2007; Cherry and Evans 2008). 
 
Single cell ERPr curves using the CRN and NYG models are shown in Figure 5.3, Ai and 
Aii. ERP under CRN SR at a PCL of 1 s for SR was seen to be 327.9 ms, under BB to be 
338.2 ms (a 3.1% increase). And under AF was seen to be 165.3 ms (a 50% reduction from 
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SR). The AFBB case gave an ERP of 179.3 ms (a 8.4% increase compared to AF). In the 
NYG model, the SR ERP at 1 s PCL was seen to be 216 ms, which increased to 286 ms 
under BB conditions (a 32% increase). Under AF conditions ERP was reduced to 154 ms 
(a 29.6% reduction), whilst AFBB gave an ERP of 173 ms (a 13% increase over the AF 
case). In both models, BB shifted ERPr rightwards, indicating the reduced ability of atrial 
cells to sustain AP excitations at high rates of pacing. BB shifted both ERPr leftwards, 
indicating the increased ability of atrial cells to sustain AP excitations at high rates of 
pacing. The effects of AFBB were to compensate this leftward shift due to AF, but had 
limited restorative effects in bringing the AF affected cellular ERPr closer to the SR ERPr. 
5.3.3 Alterations to CV due to AF and BBs 
 
CVr under SR, BB, AF and AFBB conditions were computed using 1D homogeneous 
strands of CRN and NYG virtual atrial tissue models as described in the methods section 
and are shown in Figure 5.3, Bi and Bii. Under SR conditions, the CV of solitary waves, 
i.e. at PCL exceeding 1 s, was 0.2666 mm/ms (CRN) and 0.2717 mm/ms (NYG). BB had 
no significant effect on the SR CVr. At low rates of pacing, AF was seen to reduce solitary 
wave CV from 0.27 mm/ms to 0.26 mm/ms, whilst dramatically increasing the rate at 
which electrical conduction was sustained as compared to SR conditions. The effect of BB 
on AF, i.e. the AFBB case, did not alter the AF CVr significantly and retained the tissues’ 
ability to sustain high pacing rate electrical conduction. Quantitative results are given in 
Table 5.2. 
5.3.4 Effects of AF and BB on the temporal VW 
 
TVW was computed using 1D homogeneous strands of atrial tissue based on the CRN and 
NYG models results of which are shown in Figure 5.4, Ai and Aii. Under SR conditions, 
VW was found to be 14.6 ms (CRN) and 12.1 ms (NYG). Under BB conditions the VW 
increased in the 1D strands based on the CRN model (15.7 ms), but reduced based on the 
NYG model (11.8 ms). AF conditions reduced VW (CRN: VW = 13.6 ms; NYG: VW = 8 
ms), largely due to the drastic increase of IK1 (Kharche, Garratt et al. 2008). However, 
when BB was applied to the AF affected strands, i.e. under AFBB conditions, the VW 
remained unaltered (CRN: VW = 13.2 ms) or increased (NYG: VW = 9.1 ms) as compared 
to the AF case. Overall, BB, AF and AFBB conditions gave a reduced VW as compared to 
SR conditions (Figure 5.4, Ai and Aii). Quantitative results are given in Table 5.2. 
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Figure 5.2 Simulated APD restitution curves and APDr maximal slopes for CRN (left column) and 
NYG (right column) models under Control (blue), BB (green), AF (red), and AFBB (purple) 
conditions. Ai, Aii: APDr curves. Bi, Bii: Expanded APDr curves as shown in Ai, and Aii at low 
DI (i.e. high pacing rates). Ci, Cii: Maximum slopes of APDr curves shown in Ai and Aii. 
 
 
 105 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Simulated ERP and CV restitution curves for CRN (left column) and NYG (right 
column) models under SR (blue lines), BB (green lines), AF (red lines), and AFBB (purple lines) 
conditions. Ai, Aii: ERPr curves. Bi, Bii: CVr . 
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5.3.5 Effect of  AF and BBs on spatial VW 
 
The vulnerability of atrial tissue to spatially extended ectopic events was quantified by 
computing the critical length required to induce sustained re-entrant waves. The results are 
shown in Figure 5.4, Bi and Bii. The critical length under SR conditions was found to be 
more than 49.1 mm, which is much larger than the human atrial size of approximately 40 
mm. This indicates that under SR conditions, human atrial tissue does not sustain re-
entrant activity induced due to premature stimuli. It also indicates that the length of atrial 
obstacles required to induce erratic propagations is much larger than human atrial sizes. In 
contrast, the critical length under AF conditions was found to be 17.4 mm, a much smaller 
value compared to SR. Under BB conditions, the critical length was longer than SR at 60 
mm. Under BB upon AF conditions (AFBB), the critical length was computed to be 27.5 
mm. This is modestly extended from the AF conditions but is still substantially shorter 
than in the SR case. These results indicate that BB has some limited protective effects 
when applied to tissue which has undergone AFER. The NYG simulations yielded similar 
quantative results which can be seen in Table 5.2.   
5.3.6 Re-entry in 2D homogeneous sheet models 
 
The NYG model was found to be unsuitable for prolonged simulations showing abnormal 
pace making activity due to intracellular ion accumulation, and due to its optimal operating 
pacing rate being 1 Hz. 2D and 3D simulations of re-entry and scroll waves were therefore 
carried out using the CRN model. 
 
The 2D simulations of re-entrant waves under various patho-physiological conditions is 
illustrated in Figure 5.5 and the associated spiral wave tip trace, representative time traces, 
and  PSD are shown in Figure 5.6. Under SR conditions, the re-entrant waves in the 2D 
homogeneous sheet of atrial tissue meandered over a large area. It self-terminated within 
1.4 s due to localised excitation wave fronts colliding with repolarisation tails of previous 
excitations. The rate of excitation of localised tissue was low, as revealed by a simple 
power spectrum density analysis of representative AP profiles (3.6 Hz). Under BB 
conditions, the behaviour of re-entry is similar to SR conditions. On the other hand, AF 
had a dramatically stabilising effect on re-entrant waves in a 2D idealised sheet of atrial 
tissue. Due to the large abbreviation of propagation wavelength, re-entrant waves under AF 
were highly stable with a very small area of meander. The re-entry persisted for more than 
the total simulated electrical activity of 6 s and caused a high rate of excitation of atrial 
tissue (~ 7.6 Hz, 16 Hz). In the AFBB case, the re-entry was considerably more stable than 
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in the SR case and persisted for the duration of simulated atrial activity (6 s). The power 
spectrum of AP profiles also gave higher localised pacing rates (~ 7.3 Hz, 14 Hz). Thus 
BB reduced the risk of persistent re-entry under SR conditions, although it may not be able 
to alleviate re-entry in patients with chronic AF. 
 
5.3.7 Scroll wave propagation in 3D organ model 
 
Figure 5.7 shows re-enrty simulation in a 3D atria. Under SR conditions, the re-entrant 
waves self-terminated within 4.2 s, irrespective of the location of the initiated scroll wave. 
Interactions between the arm of the scroll wave and anatomical obstacles did not cause the 
genesis of persistent erratic propagations. Localised atrial excitation was at low pacing 
rates (3.1 Hz) as demonstrated by the DF in the power spectrum of AP profiles. Scroll 
waves had a similar behaviour under BB conditions with self-termination at around 3.3 s. 
Again, the lifespan of the scroll wave did not depend upon the location of birth. Under AF 
conditions, however, the scroll wave was highly localised and stable. Eventually, 
interactions between the arm of scroll wave and anatomical obstacles caused persistent 
erratic propagations. The erratic electrical activity persisted for the whole 6 s duration of 
the simulation. Localised atrial excitation was at high pacing rates (7.6, 16 Hz). In the 
AFBB case, the scroll waves were stable and BB on chronic AF did not cause scroll waves 
to self-terminate, and persisted for the period of the simulations (6 s). 
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Figure 5.4 Temporal VW and Spatial VW simulation results for CRN (left column) and NYG 
(right column) models under Control (blue), BB (green), AF (red), and AFBB (purple) conditions. 
Ai, Aii: VW. Bi, Bii: MS. 
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Figure 5.5 Simulation of re-entry in 2D idealised sheets of virtual atrial tissue. Top panels show 
representative frames from the SR simulation, second row from BB, third row for AF and bottom 
row of panels show data for AFBB. Columns I-III show representative frames from the simulations 
at 325 ms, 875 ms and 1375 ms respectively. 
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Figure 5.6 2D spiral wave tip traces (panel i), representative AP traces taken from 2D simulations 
(panel ii), and power spectrum density showing frequencies of maximal power (panel iii) under SR 
(A), BB (B), AF (C), AFBB (D) conditions. 
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Figure 5.7 3D scroll wave simulation results. Top panels show data for Control, second row for 
BB, third row for AF and bottom panels show data for AFBB. Columns I, II, and III show panels 
from the 3D re-entry simulations at 100 ms, 2000 ms, and 4000 ms respectively. 
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Figure 5.8 Representative AP traces taken from 3D simulations (panel i), and power spectrum 
density showing frequencies of maximal power (panel ii) under SR (A), BB (B), AF (C), AFBB 
(D) conditions. 
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5.4. Conclusions and discussion 
 
5.4.1 Main findings 
 
BB target ion channel function in the atria and are routinely prescribed due to their 
recognised cardio-protective properties (Ishiguro, Ikeda et al. 2008) with varying rates of 
success. The anti-fibrillatory effects of BB on atrial tissue conduction, and on organ level 
conduction behaviour, have not been studied to date. In this study, a computational 
approach was adopted to gain insights into the cardio-protective and anti-fibrillatory 
effects of beta-blockers at tissue and organ levels. The principal findings were that the 
effects of BB on normal (SR) electrical behaviour was to prolong APD, moderately reduce 
susceptibility to ectopic activity (increased MS) and reduce lifespan of re-entrant waves at 
2D and scroll waves at organ levels. The effects of BB on AF affected cells was to 
modestly prolong APD and MS. BB however did not restore atrial excitation behaviour to 
SR conditions and re-entrant waves in 2D and scroll waves in organ level simulations were 
persistent. 
 
In conclusion, it was found that BBs have a cardio-protective effect of human atrial AP and 
electrical conduction behaviour, but cannot restore electrical properties of AF affected 
atrial tissue to SR conditions and therefore have limited applicability in the diseased stages. 
 
5.4.2 Limitations of the study 
 
The CRN and NYG models were used in this simulation study. The potential limitations 
and suitability of these models have been discussed elsewhere (Courtemanche, Ramirez et 
al. 1998; Nygren, Fiset et al. 1998; Cherry and Evans 2008). The NYG model, in 
particular, is parametrically fine tuned to reproduce human atrial APs at a pacing rate of 1 
Hz. Upon pacing at higher rates, it readily shows intracellular ion accumulation and 
depletion making it unsuitable for prolonged simulations. A limitation in our multi-cellular 
models was the presumption of electrical and spatial homogeneity, whilst it is known that 
human atria are electrically and spatially heterogeneous (Seemann, Hoper et al. 2006). In 
the simulations of the effects of AF and BB, ion current remodelling of several currents has 
been incorporated. However, it is known that AF also affects intracellular gap junctions 
(van der Velden and Jongsma 2002; Chaldoupi, Loh et al. 2009). Over and above AF 
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affecting them, beta-blockers and anti-arrhythmic drug therapies target gap junctions 
(Burashnikov and Antzelevitch 2009) as well as ion channels. Thirdly, the effects of AF 
and BB on intracellular ion dynamics has not been considered, as these could potentially 
be the basis for persistent AF (Liang, Xie et al. 2008) and also be drug therapy targets 
(Dobrev and Nattel 2008). 
 
Having identified the limitations in this computer modelling study, the fundamental 
conclusions of this study are unaffected. The structural effects of AF and BB on the human 
atria should not affect the electrophysiological functional effects demonstrated in this 
study. 
 
5.4.3 Clinical significance and comparison to previous studies 
 
Alterations in a plethora of atrial ion channels have been implicated in AF (Bosch, Zeng et 
al. 1999; Workman, Kane et al. 2001; Wettwer, Hala et al. 2004). Because age-related AF 
is connected to such AF induced electrical remodelling, several hereditary genetic defects 
have also been conclusively associated with AF (Abraham, Yang et al.; Chen, Xu et al. 
2003; Xia, Jin et al. 2005; Das, Makino et al. 2009; Watanabe, Darbar et al. 2009; Yang, 
Li et al. 2009). These experimental and clinical studies and our multi-scale computer 
modelling studies have shown that electrophysiological alterations in the biophysical 
properties of human atrial ion channels lead to the genesis and sustaining of AF (Zhang, 
Garratt et al. 2005; Kharche, Seemann et al. 2007; Kharche, Garratt et al. 2008; Kharche, 
Seemann et al. 2008; Kharche 2009; Zhang, Garratt et al. 2009). It is not surprising that 
these AF affected ion channels are drug therapeutic targets, and are being investigated 
extensively (Wijffels and Crijns 2003; Antzelevitch and Burashnikov 2009; Hundal and 
Garg 2009; Kemeny-Suss, Kasneci et al. 2009; Kozlowski, Budrejko et al. 2009; Nanda, 
Siddique et al. 2009). In particular, the anti-arrhythmogenic effects of beta-blockers have 
long been identified (Lambert 1972; Levi and Proto 1972) and beta-blockers have been 
known to reduce mortality by 25% (Yusuf, Peto et al. 1985). Beta-blockers are routinely 
prescribed in the clinic, but in recent times their effectiveness has been seen primarily in 
alleviating post-operative discomfort (Cheng and Nayar 2009; Sinha, Schwartz et al. 2009) 
rather than as an absolute pharmacological solution to AF, which is primarily a 
degenerative disorder. In fact, several anti-arrhythmic drugs used in the treatment of AF 
have been shown to result in ventricular proarrhythmia and extra-cardiac toxicity 
(Burashnikov and Antzelevitch). Atrial selective drugs at effective dosage have also been 
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shown to demonstrate adverse effects (Burashnikov and Antzelevitch 2008; Burashnikov, 
Di Diego et al. 2008; Ford and Milnes 2008). 
 
Clinical practice aside, the mechanisms by which beta-blockers may alleviate the risk of 
re-infarction in AF patients remains under investigated. In a recent experimental study on 
human atrial cells (Workman, Kane et al. 2003), beta-blockers have been shown to have a 
moderate effect on major electrical ion channels. The restorative effect on the major ion 
channels affected by AF was at most mild. The incorporation of the effects of AF into 
mathematical models showed the expected reduction of APD, ERP along with genesis of 
erratic wave propagations in an organ model. Upon simulation of treatment with beta-
blockers, the effects of AF were not alleviated and erratic propagations persisted. The 
therapeutic effects of beta-blockers on alleviating electrophysiological atrial arrhythmias 
due to re-entry are therefore limited. However, the effects of BB on limiting non-re-entrant 
cannot be ignored and therefore this area required further study.  
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Chapter 6 
 
Computational evaluation of the anti-arrhythmogenic 
effects of an IKur channel blocking agent 
 
6.1 Introduction 
 
The clinical management of AF is often via rhythm control, which is primarily achieved 
with the administration of Class I and Class III drugs. However, while interventions with 
these classes of drugs are common practice, their medium to long term effectiveness in 
maintaining sinus-rhythm (SR) is limited (Fuster, Ryden et al. 2001; de Denus, Sanoski et 
al. 2005).  Pharmacological agents aim to prevent the onset of AF by blocking key ion-
channels responsible for the repolarisation of a cardiac myocyte, thereby lengthening APD 
and ERP. Increased ERP lengthens the wavelength at which the excitable tissue of the 
myocardium can sustain a re-entrant circuit. This limits the tissues’ susceptibility to re-
entry, allowing the normal propagation of an excitation wave to be maintained. However, 
the proteins responsible for the ion-channels are actively transcribed in the ventricles as 
well as the atria, and therefore it is not possible to alter ion-channel properties with drug 
therapy in the atria without also changing the electro-physical properties of ventricular 
cells. In fact, alterations to ion-channels which are anti-arrhythmogenic in the atria can 
lead to potentially life threatening side effects such as a ventricular pro-arrhythmia. 
Current drug development therefore focuses on developing pharmacological agents which 
are atrial specific so as to limit the risk of adverse side effects (Tamargo, Caballero et al. 
2009).  
 
Possible therapeutic benefits of blocking IKur are well known and in recent years a number 
of pharmaceutical companies have attempted to develop an IKur specific channel blocking 
agent with the aim to produce a more robust method for the prevention and treatment of 
AF (Brendel and Peukert 2003; Ford and Milnes 2008). Current efforts to develop such a 
drug have resulted in the synthesis of agents which inhibit other potassium channels along 
with the calcium and sodium channels. However, it has been observed that at low micro-
molar concentrations (10–50 µmol/L),4-aminopyridine (4-AP) successfully blocks IKur 
without altering the properties of other ionic currents (Nattel, Matthews et al. 2000).  
Experimental work conducted by Wettwer et al. has extracted atrial myocyte cells from 
patients who exhibit normal sinus rhythm (SR) and patients who have been suffering from 
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persistent AF. Wetter et al. reported that applying low concentrations of 4-AP to an atrial 
myocyte under SR conditions, thereby blocking the IKur ion-channel, resulted in a 
shortening of APD. In contrast, the application of 4-AP to a cell which has undergone 
AFER resulted in a modest increase in APD.  
 
While previous experimental and simulation studies have identified that the blocking of 
IKur results in a shortneting of APD and ERP in healthy cells, and conversely a lengthening 
of APD and ERP in cells which have undergone AFER, the full effects have not been 
studied in detail at a multi-scale level. This chapter focuses on implementing single cell, 
1D, 2D, and 3D simulation protocols to investigate and quantify the underlying 
arrhythmogenic effects of blocking the IKur. Two cell types, an atrial myocyte under SR 
conditions, and an atrial myocyte which has undergone AFER. The simulated cells are 
incorporated into the standard multi-scale techniques outlined in Chapter One to 
investigate and quantify how alterations of IKur result in changes to tissue susceptibility to 
AF.  
 
6.2 Methods 
 
This section outlines the methodology behind the development of four cell types: sinus-
rhythm (SR), SR with the application of the blocking agent 4-AP (SR+B), AFER cell (AF), 
and AFER with the application of the blocking agent 4-AP (AF+B) by modifying the CRN 
(Courtemanche, Ramirez et al. 1998) model. This CRN model was implemented as it has 
been extensively used in previous simulation studies and is numerically stable under 
normal physiological conditions (Seemann, Hoper et al. 2006; Kharche, Seemann et al. 
2007; Kharche, Seemann et al. 2008; Kharche and Zhang 2008). All multi-scale techniques 
for quantising the onset of AF which are outlines in Chapter One are implemented. 
Additionally a simulation into how augmentation and the blocking of the major ionic 
current alters APD90 is performed. 
 
6.2.1 Development cell type model 
 
Experimental data from Wettwer et al. and Workman et al. indicated how the major 
currents are reduced or augmented under various conditions (Workman, Kane et al. 2001; 
Wettwer, Hala et al. 2004). This data is used to construct the four cell types by 
incorporating this scaling factor into the value of the individual ion-channel conductance’s. 
Under normal SR conditions the cell was considered to be the standard CRN model. 
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Wettwer et al. described the effect of adding 4-AP to SR cells as a reduction in the IKur 
current density of 78%. The SR+B cell was created by reducing the gKur parameter by a 
scaling factor of 78%. Workman et al. also describes ionic changes to the cell due to AFER 
(Workman, Kane et al. 2001). The changes due to AFER are a 90% increase in the inward 
rectifying potassium current (IK1), a 65% reduction in the transient outward current (Ito), a 
64% reduction in the in the late calcium current (ICaL), a 12% increase in the IKur current, 
and a 12% reduction in the sodium-potassioum exchanger pump (INaK). These are used 
when creating the AF cell by scaling the relevant conductance parameters associated with 
each current. The AF+B cell was simulated by applying a further reduction of the IKur 
current by 78% in addition to the ionic changes in the AF cell.  A summary of the 
alterations of all cell types is given in Table 6.1. 
 
Table 6.1 
Conductance Alterations of Channels due to AFER and 4-AP 
Model gK1 gto gCaL gKur gNaK 
SR+B - - - 78% ↓ - 
AF 90% ↑ 65% ↓ 64% ↓ 12% ↑ 12% ↓ 
AF+B 90% ↑ 65% ↓ 64% ↓ 75% ↓ 12% ↓ 
 
6.2.2 Simulating alteration to APD resulting from blocking and 
augmenting of conductances of the major ionic currents 
 
Recent studies, both experimental and simulated, have shown that under normal SR 
conditions the blocking of IKur results in an abbreviation of APD90. In contrast the blocking 
of IKur upon a cell which has undergone AFER results in a modest lengthening of APD90.  
Therefore it is of interest to investigate how alterations in the current density of individual 
ionic currents manifest themselves as changes in APD. The two cells, SR and AF were 
used to simulate an AP using the standard protocol as described in Chapter One. The major 
ionic currents IKur, Ik1, ICaL, and Ito were scaled through the range from 0% (total block) to 
200% (doubling the current density) to study the effects that the channel conductance has 
on the APD of the two cell types. 
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Table 6.2 Summary of cell properties for AFER and 4-AP cells 
Model Quantity SR SR+B AF AF+B 
Resting potential 
(mV) 
-80.8 -80.4 -83.9 -83.7 
APD90 (ms) 314.2 299.2 155.5 180.6 
Overshoot (mV) 24.7 24.9 24.7 24.8 
dV/dtmax (mV/ms) 217.1 216.2 205.5 205.4 
APDr maximal 
slope 
1.3 1.3 0.7 0.7 
Cell 
ERP (ms) 
(stimulus interval 
~ 1 s) 
327.9 319.8 167.7 193.5 
 Cut off BCL (ms) 328.6 417.7 312.0 265.0 
CV (mm/ms) 0.26 0.26 0.25 0.25 
Cut off S2 (ms) 320 313 198 217 
VW (ms) 14.6 14.7 15.6 14.3 
     1D 
Wavelength (mm) 81.7 77.8 38.8 45.1 
LS (s) 1.4 1.0 > 6 > 6 
DF (Hz) 3.6 4.7 8.1 8.0 
Tip meander area 
(cm
2
) 
5.25 0.9 4.0 1.5 
     2D 
MS (mm) 49.2 77.8 17.4 45.1 
LS (s) 4.2 4.1 > 6 > 6 
     3D 
DF (Hz) 3.1 2.6 7.5 6.9 
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6.3 Results of multi-scale simulations 
 
This section details the results of the simulations implemented to quantify the electrical 
behaviour at single cell, 1D strand, 2D sheet, and an anatomically correct 3D geometry. 
The results of the simulations are described along with relevant measurements which 
quantify the onset of AF, which are summarised in Table 6.2. 
 
6.3.1 Effects of AF and 4-Aminopyridine on single atrial myocyte AP 
 
AP profiles and associated major ionic currents can be seen in Figure 6.1. Under SR 
conditions the APD90 is measured to be 314.2 ms. In the SR+B cell the addition of 4-AP 
resulted in a modest abbreviation of APD90 by 4.8% to 299.2 ms. In AF cells APD90 is 
measured to be 155.5 ms, a dramatic abbreviation of 51.0% from the SR case. For the 
AF+B cell, where 4-AP is added to the AF cell, the APD90 is 52.5% shorter then in the SR 
cell at 180.6 ms but it is augmented by 16% in comparison to the AF cell. Typically an 
augmentation of APD90 results in an increase in ERP which is anti-arrhythmogenic, 
whereas a reduction in APD90 shortens ERP which is pro-arrhythmogenic. These 
simulation results show that the application of the blocking agent 4-AP to SR cells results 
in a shortening of APD90 and is pro-arrhythmogenic while conversely the application of 4-
AP to the AF cells results in a lengthening of APD90 which is anti-arrhythmogenic.  
 
The reduction of APD90 in the SR+B cell in comparison to the SR cell is due to an 
increased activation of ICaL due to the blocking of IKur. This increase of ICaL results in the 
plateau of the AP being shifted into the positive, causing several  K
+
 currents to activate 
causing rapid repolarisation in the mid to late AP. This results in a modest overall 
shortening of APD90. However, in AF cells there is substantial reduction in the ICaL current 
density due to AFER which dramatically reduces the APD90. Thus a reduction of IKur now 
increases the potential where the activation of other K
+
 repolarisation currents is less 
pronounced and so the result is a lengthening of APD90. 
 
Resting potential RP under SR conditions was measured to be -80.8 mV. Under SR+B this 
was elevated moderately to -80.40 mV indicating possible pro-arrhythmic effects of the 
application of 4-AP to a cell under SR conditions by increasing the excitability of the 
tissue. Under both AF and AF+B conditions the RP remains hyperpolarised at -83.9 mV 
and -83.7 mV respectfully, showing that the blocking of IKur had a nominal effect when 
applied to cells which have undergone AFER. The hyperpolarised RP is explained by the 
 121 
augmentation of Ik1 which is primarily responsible for the resting potential. These results 
indicate that AFER reduces the excitability of the atrial cell and the blocking of IKur has a 
limited effect. 
 
The maximal upstroke velocity in the SR case was measured to be 217.1 mV/ms. Under 
AF conditions this was reduced by 5.3% to 205.5 mV/ms. Under SR+B conditions the 
maximal slope was reduced modestly by 0.4% to 216.2 mV/ms. However in the AF+B 
case there is no significant change in the value of the upstroke velocity.  
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Figure 6.1 Simulated AP profiles and major ionic currents traces for no SR (blue lines), 
SR+B block (green lines), AF (red lines), and  AF+B (purple lines) conditions where Ai, 
Aii: shows the AP. Bi, Bii: IKur. Ci, Cii: Ik1. Di, Dii: ICaL. Ei, Eii: INaCa. Fi, Fii: 
Ito.hyperpolarized RP, and elevated plateau-potentials in the early repolarisation phase. 
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6.3.2 Alterations of APD due to reduction and augmentation of ion-
channel conductance 
 
Alterations due to the augmentation and blocking of the major ionic currents under AF and 
SR conditions can be seen in Figure 6.2. Under SR and AF conditions the measured APD90 
was 314.2 ms and 155.5 ms respectively. Figure 6.2A shows that the blocking of IKur up to 
70% under SR conditions results in a shortening of APD90 by 4.9% to 299 ms. Increasing 
IKur by 30% is observed to result in an slight lengthening of APD by 0.6% to 316.2 ms. It is 
noted that augmenting and blocking IKur under SR conditions results in minimal alterations 
in APD90 overall.  Conversely, under AF conditions the blocking of IKur results in an 
augmentation of APD90, where APD90 increases until full channel block is achieved. Here 
the APD90 is simulated to be increased by 21.8% from AF conditions to 189.4 ms. The 
overall effect of modifying IKur on APD90 is therefore much greater than under SR 
conditions.  
 
Alterations in Ito under SR and AF are shown in Figure 6.2B. Under normal SR the 
augmentation of Ito up to 180% results in a lengthening of APD90 to a maximum of 381 ms. 
An increase in Ito current density of 180% results in a shortening of APD90. The blocking 
of Ito results in a consistent shortening of APD90 until full block is achieved, where the 
APD90 is found to be 276 ms. Under AF conditions a reduction of the current causes a 
modest lengthening of APD90 before reaching a plateau at full block where the APD90 is 
measured to be 158 ms. However, augmentation of Ito in the AF case results in a modest 
but sustained shortening of APD90.  
 
Figure 6.2C show alterations to APD90 resulting from alterations to the IK1 current. In both 
cases, SR and AF, an increase in conductance results in a reduction of APD90. However, 
the blocking of IK1 in both cases results in a large increase in the APD90. Blocking of 60% 
in the SR case results in an APD90 of 437.9 ms and blocking on 80% under AF conditions 
resulted in an APD90 of 508.9 ms.  
 
Figure 6.2D show alterations to APD90 due to changes in the ICaL conductance. In both SR 
and AF cases increasing and reducing channel conductance results in a lengthening and 
shortening of APD90 respectfully. 
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Figure 6.2 Alterations to APD90 due to augmentation and blocking of major ionic currents under 
SR (blue lines) and AF (red lines) cells for A: IKur, B: Ito, C: Ik1, and D: ICaL. 
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6.3.3 The effects of AF and 4-Aminopyridine on APD, ERP, and CV 
restitution curves 
 
The rate dependant nature of APDr curves can be seen in Figure 6.3A. It is observed that 
under SR+B conditions at DIs greater then 200 ms the APD90 is consistently higher than 
under SR conditions by approximately 15 ms. At DI shorter than 200 ms the APD90 
difference between SR and SR+B increases indicating that possible arrhythmogenic effects 
due to SR+B become more pronounced at high pacing regimes. Under AF conditions the 
APD90 is observed to be significantly shortened from the SR case over the full spectrum of 
DIs. AF+B conditions result in a consistent lengthening of APD90 over all DI in 
comparison to AF. The lengthening of APD90 indicates the anti-arrhythmic effects of the 
block remain, even in a high pacing regime. The measured maximal slope of the restitution 
curves are shown in Figure 6.3B.  
 
The rate dependence of the ERP is shown in Figure 6.3C. Under SR conditions the ERP at 
a PCL of 1000 ms was measured to be 327.9 ms with a cut off PCL of 328.6 ms. Under 
SR+B conditions the ERP was reduced by 2.5% to 319.8 ms indicating that the addition of 
the blocking agent increases the susceptibility to AF. However, it is observed that at high 
PCLs there is a sudden dramatic reduction in ERP and the cut off PCL is measured to be 
417.7 ms, 27.1% higher than under SR conditions. This indicates that blocking IKur under 
SR conditions provides a possible anti-arrhythmogenic mechanism by limiting the cells’ 
ability to initiate a successful AP in a high pacing regime. Under AF conditions the ERP is 
reduced to 167.7 ms which is 48.8% shorter than the SR case and the cut off BCL was 
measured to be 312.0 ms, a 5.1% reduction from the SR case. In the AF+B case the ERP 
was found to be reduced by 41.0% measuring 193.5 ms and the cut-off BCL was found to 
be reduced by 19.4% to 265.0 ms. This indicates that the addition of 4-AP under AF 
conditions reduces the excitability of the tissue by increasing ERP from AF conditions. 
However, it also increases the cut-off BCL meaning that excitability remains possible in a 
high pacing regime.  
 
The CVr curves can be seen in Figure 6.3D. At a PCL of 1000 ms the CV under SR and 
SR+B were measured to be 0.26 mm/ms and CV in the cases of AF and AF+B were 
measured to be 0.25 mm/ms, indicating that the addition of the block did little to alter the 
CV at long PCLs. However, the restitution curves in Figure 6.4D illustrate that SR+B 
results in a shift of the restitution curve in the negative direction, which is an indication of 
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sustained wave propagation at high pacing rates. This contrasts with the AF+B results that 
show a shift of the CVr curve in the positive direction from the AF case indicating a loss of 
excitation at high pacing lengths, suggesting that under AF conditions the blocking of IKur 
has an anti-arrhythmogenic effect.  
 
6.3.4 Effects of block on the temporal and spatial vulnerability window 
 
The TVW was calculated using the 1D strand of tissue and is shown in Figure 6.4E.  Under 
SR conditions the VW was measured to be 14.6 ms. Under SR+B conditions the TVW is 
increased marginally to 14.7 ms. In the AF case the VW is increased by 6.85% to 15.6 ms. 
However, under AF+B conditions the VW is returned to a slightly reduced value than 
under SR conditions measuring 14.3 ms. This is an indication that the blocking agent 4-AP 
is anti-arrhythmogenic when applied under AF conditions. 
 
The SVW as calculated by applying a stimulus to an idealised 2D homogenous sheet is 
shown in Figure 6.3F. In the SR case the MS required to initiate re-entry was measured to 
be 49.2 mm. Under SR+B conditions the MS required for re-entry is increased 
substantially by 58.2% to 77.8 mm. In the AF case the MS is reduced by 22.2% to 17.4  
mm. Under AF+B conditions the MS is measured at 45.1 mm, this is still 9% shorter than 
under SR conditions but is 259% longer than under AF conditions. This indicated that the 
blocking agent 4-AP is anti-arrhythmogenic when applied to both SR and AF cells. 
However, the application of 4-AP under AF conditions provides a restorative effect 
increasing MS to a value closer to SR conditions. 
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Figure 6.3 Simulated APDr (A), maximal slope (B), ERPr (C), CVr (D), Temporal VW (E), and 
spatial VW (F) under SR (blue), SR+B (green), AF (red), and AF+B (purple) conditions. 
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6.3.5 Simulated re-entry in a homogenous 2D sheet of atrial tissue 
 
2D re-entry simulations are shown in Figure 6.4, while spiral tip traces, time-traces, and 
power density spectrum are shown in Figure 6.5. Under SR conditions the lifespan of the 
initiated spiral waves is measured to be 1.4 s before the tip of the spiral wave meanders off 
the 2D sheet. The DF was measured at 3.6 Hz and the tip meander area was 5.25 cm
2
. 
Under SR+B conditions there is a dramatic shortening of lifespan of the spiral wave to 1.0 
s and the measured dominant frequency was recorded to be 4.7 Hz. However, the tip 
meander area is reduced substantially due to the application of the blocking agent 4-AP 
under SR conditions, although it is important to note that measurements of the tip meander 
area and DF may be misleading due to the short lifespan of the re-entrant wave. In the AF 
case the initiated spiral wave persists for the lifetime of the simulation, the dominant 
frequency increases to 8.1 Hz, and the tip meander area is reduced to 4 cm
2
. Under AF+B 
conditions the addition of 4-AP is observed to result in a failure to breakup the spiral wave 
in the period of the simulation as it is seen to persist over the lifetime of the simulation. 
However, the tip meander area is reduced to 1.5 cm
2
 which may have important 
consequences when used in conjunction with surgical intervention in that the ablation area 
required may be smaller. 
6.3.6 3D Simulation of a detailed anatomical correct construct of the 
atria 
 
3D simulations are shown in Figure 6.6 and corresponding time traces DF are shown in 
Figure 6.7. Under SR conditions it is observed that the re-entrant waves terminate after 4.2 
s and the dominant frequency is measures to be 3.1 Hz. Under SR+B conditions the 
addition of the blocking agent results in a moderate reduction of LS and DF from SR 
conditions to 4.1 s and 2.6 Hz respectively. In the AF case the stable spiral wave is born 
which persists for the lifetime of the simulation and has a dominant frequency of 7.5 Hz. In 
the case of AF+B the re-entrant wave persists for the period of the simulation and the 
dominant frequency is also reduced moderately from AF conditions to 6.9 Hz. The anti-
arrhythmic property that the addition of the blocking agent has is observed in a reduction 
of the power of the re-entrant wave. 
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Figure 6.4 Simulation of 2D re-entry in an idealized sheets of virtual atrial tissue under SR, SR+B, 
AF, and AF+B conditions. Panels show 3 s of simulation starting from 0 ms in the top left panel 
progressing in 100 ms intervals horizontally from left to right until the bottom right panel. 
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Figure 6.5 2D spiral wave tip traces (panel i), representative AP traces taken from 2D simulations 
(panel ii), and power spectrum density showing frequencies of maximal power (panel iii) under SR 
(A), SR+B (B), AF (C), AF+B (D) conditions. 
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Figure 6.6 Simulation of re-entry in a 3D geometry of the human atria under SR, SR+B, AF, and 
AF+B conditions. Panels show 6 s of simulation starting from 0 ms in the top left panel progressing 
at 300 ms from left to right until bottom right panel. 
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Figure 6.7 AP traces taken from 3D simulations (panel i), and power spectrum density showing 
frequencies of maximal power (panel ii) under SR (A), SR+B (B), AF (C), AF+B (D) conditions. 
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6.4 Conclusions and discussion 
 
6.4.1 Main findings 
 
This simulation study indicates that the blocking of the IKur channel under normal SR 
conditions results in a reduction of APD and ERP which may enhance the arrhythmogenic 
effects. However, the blockage of IKur under AF conditions results in a prolongation of AP 
causing an increase in ERP. While simulations in the single cell indicate the anti-
arrhythmic effects of blocking the IKur current, the 2D and 3D simulations show that 
blocking IKur does not aid in the break-up of re-entrant spiral waves. Blocking IKur does, 
however, result in a reduction of the power of the re-entrant waves in both the 2D and 3D 
simulations. Moreover, in the 2D simulation the tip meander area is reduced substantially. 
This suggests that the blocking of the IKur channel via drug intervention alone may not be 
effective in alleviating the onset of AF, meaning that drug administration in conjunction 
with surgical intervention may be what is required to increase the probability of a 
successful treatment.   
 
6.4.2 Limitations of the study 
 
The potential limitations of the Courtemanche et al. model used in this study have been 
discussed previously (Courtemanche, Ramirez et al. 1998; Cherry and Evans 2008). A 
limitation of the 3D simulations is the absence of heterogeneity in the structure of the atria,  
as the structure only consists of atrial cell types while it is known that cells in different 
regions of the atria have different electro-physical properties (Seemann, Hoper et al. 2006).  
Spatial heterogeneities due to fiber orientation are also neglected in the simulations as a 
uniform diffusion tensor has been implemented. 
 
6.4.3 Clinical significance and comparison to previous studies 
 
Atrial selective drugs which target ion-channels only present in the atria, such as IKur, 
provide an attractive target for drug therapy in the treatment of AF without adversely 
affecting the electrophysiological functions of the ventricles. However, while blocking of 
the IKur channel has been shown both experimentally and with simulations to prolong APD 
in cardiac myocytes which have undergone AFER, current pharmacological agents which 
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block IKur, such as Vernakalant and AZD7009, also block the sodium current (INa).Another 
agent, AVE0118, also blocks the transient outward current (Ito). These result in long term 
complications if administered for extended periods of time. Our simulations confirm that 
the blockage of  IKur for patients who have undergone electrical remodelling may limit the 
occurrence of AF and aid in rhythm control, although this is not effective once a spiral 
wave has been initiated.  
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Chapter 7 
 
Simulation of AF in a 2D caricature of a human 
heterogeneous Atrium 
 
7.1 Introduction  
 
Previous chapters of this thesis have studied how remodelling of ionic currents due to 
various external factors reduces atrial ERP, thereby increasing the tissues susceptibility to 
the genesis and maintenance of AF. This was observed in the multi scale simulations as the 
existence of stable spiral rotors in the homogenous 2D sheet and the detailed 3D 
anatomical representation of the atria. However, in these simulations the tissue was 
assumed to be homogenous, both electrically, in term on uniform cell properties, and 
structurally, in terms of the absence of fibre orientation. In reality the myocardium of the 
atria consists of multiple regions of differing tissue types each possessing their own 
distinct electrophysiological properties. In addition to electrical heterogeneities the 
presence of fibre orientation results in non uniform diffusion of electrical excitation waves, 
which is manifested as anisotropic wave propagation in the atria. Previously studies have 
identified that heterogeneities between different cell types in the in atrial tissue are an 
important factor in re-entrant activity (Coronel, Wilms-Schopman et al. 1992; Kumagai, 
Khrestian et al. 1997; Bernus, Zemlin et al. 2005). As heterogeneities within the atria have 
been ignored previously in this thesis this chapter aims to study their effects on re-entry by 
performing simulations on a simplified 2D model of the RA.  
 
A 2D atrial sheet was constructed from an image of the RA where regions of differing cell 
types were identified and simulated by modifying an atrial cell model in accordance with 
available physiological data. Simple fibre orientation was simulated via the incorporation 
of a non-uniform diffusion tensor into the 2D diffusion equation (Panfilov and Keener). In 
addition to studying the effects that electrical and structural heterogeneities play in a 
healthy heart experimental data on ion channel remodelling due to AFER was incorporated 
into the cell models allowing for an investigation on the role that heterogeneities play in 
tissue which has been electrically remodelled due to AF (Bosch, Zeng et al. 1999; 
Workman, Kane et al. 2001).  
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7.2 Methods 
 
In this methods section alterations to an atrial cell model to simulate the electrophysiology 
of the multiple cell types found in the atria and the ionic changes as a result of AFER based 
on experimental data from Workman et  al. and Bosch et  al. are also described. In 
addition, the construction of an electrically and spatially homogenous 2D atrial geometry, 
which was developed in our lab, is also outlined. 
 
7.2.1 Construction of different cell types and alterations due to AFER 
 
As in previous chapters the biophysically detailed human atrial cell model developed by 
Courtemanche et. al. (Courtemanche, Ramirez et al. 1998) was chosen for this study. The 
three main cell types found in the human atrium namely, Crystal Terminalis (CT), 
Pectinate Muscle (PM), and Atrial Cells (AT) were constructed by modifying the CRN 
model in accordance with experimental data (Seemann, Hoper et al. 2006). The ionic 
changes due to cell types are summarized in Table 7.1. In brief the changes are in PM 
muscle gCaL is increased minutely from 0.012375 nS/pF to 01238 nS/pF. In CT gto is 
increased 30.2% from 0.1625 nS/pF to 0.2115 nS/pF and gCaL is increased 67.0% from 
0.12375 nS/pF to 0.2067 nS/pF. Each of these cells types were further modified in 
accordance with a previous study to incorporate AFER from a period of 1 (Bosch) and 6 
(Workman) months (Bosch, Zeng et al. 1999; Workman, Kane et al. 2001).  The ionic 
channel remodelling in Bosch is by modeled by a 235% increase in IK1, 74% down 
regulation of ICa,L, 85% down regulation of Ito, a shift of -16 mV in the Ito steady-state 
activation, and a -1.6 mV shift of sodium current (INa) steady state activation. Fast 
inactivation kinetics of ICaL is slowed down, and was implemented as a 62% increase in the 
time constant. The ionic channel remodelling in Workman is simulated by a 90% increase 
in the inward rectifier potassium current (IK1), 64% down regulation of the L-type calcium 
current (ICa,L), 65% down regulation of the transient outward current (Ito), 12% up 
regulation of the sustained outward potassium current (IKsus), and a 12% down regulation 
of the sodium potassium pump (INa,K). The effects of these electrophysiological changes 
have on the properties of the cell are quantified through single cell and 1D simulations as 
outlined in Chapter 1.  
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Figure 7.1 Schematic of the 2D atria showing the location AT cells (green), CT cells (red), and PM 
cells (blue), and the approximate location of the SA node in indicated as a black circle. Fiber 
orientation is represented by arrows. The fiber orientation is indicated by arrows, in AT tissue there 
is no fiber orientation, in CT tissue the fiber orientation in runs north to south, and in PM the fiber 
orientation as running south-west to north-east. 
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7.2.2 Construction of 2D geometry to simulate re-entry 
 
 
To simulate the spatial heterogeneity of cell types within the RA a laboratory photograph 
of the RA was digitised at a spatial resolution of 0.1 mm. The constructed 2D sheet is 
shown in Figure 7.1. Different cell types were identified via visual inspection and thus the 
image was segmented into the distinct tissue types AM, PM and CT. Fibre orientation is 
assumed to be uniform in the AT tissue, running north to south in CT tissue, and north east 
to south west in PM tissue. The complete 2D sheet has a size of 130 x 100 mm and 
consisted of approximately 1 million active grid points. Propagation of action potential 
across the 2D sheet was calculated using the diffusion equation as shown in Equation 1.3. 
Incorporating a non-uniform diffusion tensor in to the 2D diffusion equation simulates 
fiber orientation. This tensor is altered depending on the fibre orientation of the region in 
which the cell is located (Panfilov and Keener). 
 
7.2.3 2D Simulation and initiation of re-entry with an ectopic beat 
 
To study the effects of electrical and spatial heterogeneities on re-entry four different 2D 
simulation setups were constucted, electrically and spatially homogenous (Hom-Hom), 
electrically heterogeneous and spatially homogenous (Het-Hom), electrically homogenous 
and spatially heterogeneous (Hom-Het), and electrically and spatially heterogeneous (Het-
Het). Re-entry was initiated with a S1-S2 stimulation protocol which is shown in Figure 
7.2 where an initial circular stimulus was applied with a radius r and stimulation strength 2 
nS/pF for duration of 2 ms at the approximate location of the SA node. After a short delay 
a second stimulus S2 with a similar size and strength is applies close to the site of the S1 
stimulus to initiate re-entry; simulations were performed for duration of 6 s. 
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Figure 7.2 Stimulation protocol to initiate re-enrty in an electrically and spatially heterogeneous 
2D construct of the RA. Snapshots of re-enrty protocol begin in the top left hand corner and 
progress in consecutive rows from left to right. An initial circular stimulus (S1) located near the 
location of the SA node is applied, a time later (∆T) a second stimulus (S2) of similar size and 
strength is applied initiated to simulate an ectopic beat. 
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Table 7.1 Alterations to CRN parameters to simulate AT, PM, and CT cells under Control, Bosch, and Workman conditions 
  AT   PM   CT  
Parameter Control Bosch Workman Control Bosch Workman Control Bosch Workman 
gto 
 (nS/pF) 
0.1652 
0.0248 
(85% ↓) 
0.0578 
(65% ↓) 
0.1652 (0%) 
0.0248 
(85% ↓) 
0.0578 
(65% ↓) 
  0.2115 
(28% ↑) 
0.0317 
(80.8% ↓) 
0.0740 
(55.2% ↓) 
gCaL 
(nS/pF) 
0.1238 
0.0322 
(74% ↓) 
0.0446 
(64% ↓) 
0.1238 
(0%) 
0.0322 
(74% ↓) 
0.0446 
(64% ↓) 
0.2067 
(67% ↑) 
0.0537 
(56.6% ↓) 
0.0744 
(39.9 %↓) 
gK1 
 (nS/pF)
 0.09 
0.3015 
(235%↑) 
0.1710 
(90% ↑) 
0.09 
(0%) 
0.3015 
(235%↑) 
0.1710 
(90% ↑) 
0.09 
(0%) 
0.3015 
(235%↑) 
0.1710 
(90% ↑) 
gKur* (nS/pF) gKur gKur 1.12*gKur gKur gKur 1.12*gKur gKur gKur 1.12gKur 
INaK (max) 
(nS/pF) 
0.06 
0.06 
(0%) 
0.0528 
(12% ↓) 
0.06 
0.06 
(0%) 
0.0528 
(12% ↓) 
0.06 
0.06 
(0%) 
0.0528 
(12% ↓) 
Ito-act-shift 0 - 16 0 0 -16 0 0 -16 0 
Ina-act-shift 0 -1.6 0 0 -1.6 0 0 -1.6 0 
τf τf τf 0.38τf τf τf 0.38τf τf τf 0.38τf 
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7.3. Results of multi-scale simulations 
 
This section describes how alterations to ion channel kinetics due to differing cell types 
and AFER alter the behaviour of cell and provides measurements which indicate the cells 
susceptibility to the onset of AF at a single cell and 1D level, a summary of which is 
shown in Table 7.2. Simulations showing the results of incorporating electrical and spatial 
heterogeneities into the 2D atrial sheet are also described. 
7.3.1 Single cell simulations 
 
AP profiles and calcium transients for AT cells can be seen in Figure 7.3Ai and 7.3Aii 
respectfully. Under Control conditions the APD90 is measured to be 312.9 ms. This is 
reduced drastically under Workman conditions to 147.6 ms (52.8% reduction) and is 
further reduced in the Bosch case to 108.5 ms (65.3% reduction). PM cells APD90 is 
similar to that of AF due to their similar electrophysiology. For CT cells under Control 
conditions the APD90 was measured to be 333.1 ms which is a prolongation of 6.4% 
compared to the AT Control case. Under Workman conditions the APD90 is shortened to 
181.0 ms (45.6% reduction) and 136.6 ms (41.0% reduction) for Bosch conditions. These 
results indicate that AFER is arrhythmogenic due to the shortening of APD. However, it is 
noted that reductions to APD90 for CT cells result in a less dramatic shortening of APD90 
which indicated CT cells may be more resistant to the genesis of AF than its AT and PM 
cell counterparts. 
 
 
The RP for AT cells under Control conditions is measure to be -81.2 mV. AFER results in 
a hyperpolarized RP from -83.9 mV (3.8% reduction) under Workman conditions and 
(5.4% reduction) to -85.2 mV for Bosch conditions. PM cells show similar alterations as 
AT cells due to near identical electrophysiology. CT cells under SR conditions have in a 
hypo-polarised RP of -80.3 mV (1.1% increases) compared to AT cells under Control 
conditions. Under AFER conditions for Workman and Bosch conditions the RP are 
measured to be -83.8 ms (6.2% reduction) and -85.2 mV (6.2% reduction) respectfully. 
These results show that under SR conditions the CT cells have a hypopolarised RP which 
increases the cells excitability to stimulus. However, for cells which have undergone 
AFER there is little difference in RP between cell types. 
 
For AT cells under SR conditions the dV/dtmax was measured to be 217.1 mV/ms. In cells 
which have undergone AFER the dV/dtmax for Workman and Bosch cells was found to be 
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206.66 mV/ms (4.8% reduction) and 205.56 mV/ms (5.3% reduction) respectfully. The PM 
cells show similar results due to near identical electrophysiology. In CT cells under 
conditions the dV/dtmax was measured to be 215.23 mV/ms; a modest reduction from the 
AT cell SR case of 0.8%. However, in the AFER CT cell dV/dtmax remained similar in 
value to AT cells measuring 206.6 mV/ms and 205.52 mV/ms for Workman and Bosch 
respectfully.
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Table 7.2 Summary of quantitative results for AT, PM, and CT cells under Control, Bosch, and Workman conditions 
   AT   PM   CT  
Model Quantity Control Workman Bosch Control Workman Bosch Control Workman Bosch 
Resting potential 
(mV) 
-81.2 -83.90 -85.23 -81.2 -83.90 -85.23 -80.25 -83.84 -85.20 
APD90 (ms) 312.9 147.63 108.53 312.9 147.65 108.55 333.09 181.01 136.64 
Overshoot (mV) 24.8 25.01 24.88 24.8 25.01 24.88 24.86 25.10 24.91 
dV/dtmax (mV/ms) 217.1 206.66 205.65 217.1 206.66 205.65 215.23 206.59 205.52 
APDr maximal slope 1.3 1.7 4.1 1.3 1.7 4.1 1.6 2.3 4.9 
Cell 
ERP (ms) (stimulus 
interval ~ 1 s) 
327.9 165.1 122.1 327.9 165.1 122.1 344.0 189.2 146.0 
 ERP cut off (ms) 324 163 110 324 163 110 329 193 132 
CV (mm/ms) 0.266 0.255 0.247 0.266 0.255 0.247 0.267 0.255 0.247 
CVcut off (ms) 303.5 184.4 142.7 303.6 184.4 142.7 318.5 209.8 161.7 
VW (ms) 14.6 12.9 12.5 14.6 12.9 12.5 13.3 12.8 12.7 
1D 
Wavelength (mm) 83.2 37.6 26.8 83.2 37.6 26.8 88.9 46.2 33.8 
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Figure 7.3 Simulated AP profiles and calcium transient current traces where Ai: Control AP 
profile. Aii: Control Ca2+ current trace. Bi: Workman AP profile. Bii: Workman Ca2+ current trace. 
Ci: Bosch AP profile. Cii: Bosch Ca2+ current trace. D: Bar chart showing APD90 for AT, PM, and 
CT under Control, Bosch, and Workman conditions.  
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7.3.2 APD, ERP, and CV restitution curves 
 
APDr curves in Figure 7.4A show that for AT cells the APD is reduced over the full 
spectrum of DI when the cells undergo AFER cases, it is also noted that under Bosch 
conditions the APD90 is reduced still further over the range of measured DIs. For PM cells 
the restitution curves are not visible as they lie beneath the AT cell curves due to their 
similar electrophysiology. For AT and PM cells the maximal slope under SR conditions is 
measured to be 1.3, under Workman conditions this is increased by 66.9% to 1.7 and for 
Bosch still further by 413.1% to 4.1.  For CT cells the maximal slope under SR conditions 
was 1.6, a 61.5% increase from the AT SR case. Under Workman conditions this increased 
by 42.9% to 2.3 and further increased by 305.7% to 4.9 in the Bosch case. An increase in 
maximal slope indicates that a stable spiral wave is more likely to manifest its self 
indicating the tissues increased susceptibility to AF. If is observed that the AFER increased 
the maximal slope substantially in the remodeled cells of Bosch and Workman. However, 
the ionic changes to model the electrophysiology of the CT cell under SR conditions result 
in an increased maximal slope, this suggests that tissue constructed of CT cells will be able 
to sustain re-entry. 
 
ERPr curves are shown in Figure 7.4B. Workman conditions result in a leftward shift of 
the curves indicating increased excitability at higher pacing frequencies, Bosch conditions 
result in a greater shift that Workman indicating Bosch further increases excitability at 
even higher pacing lengths. For AT and PM cells under SR conditions the ERP  is 
measured to be 327.9 ms. For CT cells this is increased by 5.0% to 344.0 ms. Under 
Workman conditions the EPR for AT and PM  cells is reduced from Control conditions by 
49.6% to 165.1 ms and 42.2% to 189.2 ms for CT cells. In the Bosch case the ERPs are 
reduced further where AT and PM are reduced by 62.7% to 122.1 ms and CT was reduced 
by 55.4% to 146.0 ms. Reductions in ERP due to AFER indicate the tissues ability to 
maintain wave propagation in a high pacing regime. It is also noted that changes to the 
electrophysiology of CT cells increases the ERP modestly therefore may provide 
conduction block in a high pacing regime. The EPR curve cut off points also shows a 
leftward shift further indicating that the cell had increased ability for maintaining wave 
propagation in a high pacing regime due to AFER. There was a modest shift in cut off 
ERPs in CT cells which may also provide conduction block in a high pacing regime. 
 
The CVr curves are shown in Figure 7.4C. For AT, PM and CT cells the CV at PCL of 
1000 ms under SR conditions was measured to be 0.266 mm/ms, under Workman 
conditions this is reduced by 4.1% to 0.255 mm/ms, and in the Bosch case the CV is 
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further reduced by 7.1% to 0.247 mm/ms. These results indicate that AFER reduced the 
CV of wave propagations which therefore reduces the wavelength at which the tissue can 
sustain a re-entrant circuit increasing the ability of the tissue to sustain re-entrant waves. 
However, in a low pacing regime it was noted that there is no difference between the 
various cell types. For AT and PM cells the electro physical change due to AFER result in 
a leftward shift of the CVr curve. Under SR condition the cut off PCL was measured to be 
303.5 ms, under Workman conditions this was shifted leftward by 39.2% to 184.4 ms, and 
further still in the Bosch case by 52.9% to 142.7 ms. For the CT cells under SR conditions 
the cut of PCL is measured to be 318.5 ms, this is a shift in the positive direction of 4.9% 
when compared to the cut off PCL of AT cells. Under Workman conditions CT cut off 
PCL is measured to be 209.8 ms, this is a shift in the positive direction of 13.7% when 
compared to the cut off PCL of AT cells under Workman condition. Under Bosch 
conditions CT cut off PCL is measured to be 161.7 ms, this is a shift in the positive 
direction of 13.3% when compared to the cut off PCL of AT cells under Bosch condition.  
This left ward shift of CVr curves indicate the possibility of AF genesis as the tissues 
increased its ability of wave propagation in a high pacing regime. Interestingly, 
electrophysical changes due to the CT cells result in a rightward shift of the CVr curves for 
cells which have undergone AFER. 
 
The TVW shown in Figure 7.4D for AT and PM cells under SR conditions was measured 
to be 14.6 ms. Under Workman conditions the VW is reduce by 11.4% to 12.9 ms. This is 
further reduced under Bosch conditions by 14.5% to 12.5 ms. The TVW for CT cells under 
SR conditions was 13.3 ms which is 9.0% shorter than the AT SR case. Under Workman 
conditions TVW is 12.8 ms, a reduction 4.0% from SR CT case. In the Bosch case the 
TVW is further shortened by 4.6% to 12.7 ms.  
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Figure 7.4 Simulated restitution curves for AT (solid lines), PM (dotted lines), and CT (dashed 
lines) cells under Control (blue lines), Workman (green lines), and Bosch (red lines) conditions 
where (A) shows APDr curves. (B) Shows ERPr curves. (C) Shows ERPr curves. (D) Shows TVW. 
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Figure 7.5 Shows snapshots from electrically and spatially homogeneous 2D atrial sheet 
simulations consisting of only AT cells at time steps of 300 ms, 600 ms, 900 ms, 3000 ms, 4000 ms 
and, 5000 ms under Control, Bosch, and Workman conditions. 
 
 149 
 
 
 
 
 
 
 
Figure 7.6 Shows snapshots from electrically homogeneous and spatially heterogeneous 2D atrial 
sheet simulation where only AT cells are present but with fiber orientation in included at time steps 
of 300 ms, 600 ms, 900 ms, 3000 ms, 4000 ms and, 5000 ms under Control, Bosch, and Workman 
conditions. 
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Figure 7.7  Shows snapshots from electrically heterogeneous and spatially homogenous 2D sheet 
simulation where the atrium consisting of AT, CT, and PM cells and fiber orientations included at 
time steps of 300 ms, 600 ms, 900 ms, 3000 ms, 4000 ms and, 5000 ms under Control, Bosch, and 
Workman conditions.  
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Figure 7.8 Shows snapshots of electrically and spatially heterogeneous 2D sections of the atrium 
consisting of AT, CT, and PM cells and with fiber orientation incorporated at time steps of 300 ms, 
600 ms, 900 ms, 3000 ms, 4000 ms and, 5000 ms under Control, Bosch, and Workman conditions.  
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7.3.3 2D atrial sheet simulations 
 
Simulations performed on a 2D atrial sheet under a combination of electrical and spatial 
heterogeneities are shown in Figures 7.6-9 and associated power spectrums are shown in 
Figure 7.9. Electrically and spatially homogenous simulations where the 2D atrial 
construct consists of only AT cells are shown in Figure 7.5. Under Control conditions the 
ectopic beat fails to initiate persistent re-entry. In both Workman and Bosch cases the 
ectopic beat initiates stable re-entrant waves which persist for the duration of the 
simulation (6 s). Tissue simulations for electrically homogenous and spatially 
heterogeneous where the tissue consists of only atrial cells are shown in Figure 7.6. In the 
Control case the initiation of the ectopic beat again fails to initiate re-entry. In Workman 
and Bosch cases stable spiral waves are born which persist for the period for the period of 
the simulation. It is observed that the fiber orientation present in the PM result in a non 
uniform wave propagation, again this effect is most noticeable in the Bosch case.  Tissue 
simulations for electrically heterogeneous and spatially homogenous are shown in Figure 
7.7. In the Control case the ectopic beat fails to initiate re-entry but and re-enrty is 
observed to be born and persists in the Workman and Bosch cases for the duration of the 
simulation. It is observed that the boundary between AT can CT results in multiple 
wavelets being born. Tissue simulations for electrically heterogeneous and spatially 
heterogeneous are shown in Figure 7.8. Heterogeneities in the SR conditions aid spiral 
wave break up. However these heterogeneities in the AF cases result in multiple spiral 
wavelets being born due to fiber orientation and difference in cell properties. In conclusion 
it is observed that heterogeneities present in the RA may aid in the termination of AF when 
the cells are healthy. However, if the cells have undergone AFER then the heterogeneities 
allow for genesis of multiple wavelets. The power spectrum in Figure 7.9 shows that the 
DF under Control conditions is 3 Hz, under Workman conditions this is augmented to 8 Hz 
and in the Bosch case the DF is increased to 10 Hz. These results indicate that 
electrophysiological changes due to AFER allow for higher frequency oscillations.  
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Figure 7.9 Frequency plots for Hom-Hom, Hom-Het, Het-Hom, and Het-Het under Control, 
Workman, and Bosch conditions. DF under Control conditions is 3 Hz, under Workman 
conditions this is augmented to 8 Hz and in the Bosch case the DF is increased to 10 Hz. 
This indicates that electrophysiological changes due to AFER allow for higher frequency 
oscillations. 
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7.4. Conclusion and discussion  
 
7.4.1 Main findings  
 
The single cell simulations indicate the pro-arrhythmic effects of AFER in AT, CT, and 
PM cells are characterised by a shortening of APD, increase in dV/dTmax, reduction or 
ERP, and shortening of VW. In addition electrophysiological changes due to varying cell 
type results in a diversion of APDs.  Recent clinical work has identified that structures 
within the atrium are an important consideration when studying the generation and 
maintenance of AF (Wu, Yashima et al. 1998). These structures present themselves as a 
catalyst for the genesis of re-entrant waves due to their differing electrophysiological 
properties. The borders between regions between cell types has been identified as to 
provide an anchor point for spiral rotors (Wieser, Nowak et al. 2008). When performing 
simulations in the 2D atrial sheet the variations in APD between AT, PM and CT cells at 
the borders provide a mechanism by which re-entrant waves are initiated. It is observed 
that these modest variations in between cell types aid in the breakup of re-entry waves 
under SR conditions. However, under Workman and Bosch conditions the heterogeneities 
between cell types in increased aiding in maintenance of AF where the CT cells appear to 
act as an anchor for the re-entrant circuit. 
7.4.2 Limitations of simulations 
 
As in the other chapters the CRN model was implemented, the suitability of using this 
model has been discussed previously. Limitations in the study arise on the assumption that 
the three different cell types lie in distinct regions separated by a clear boundary. In reality 
these borders have a transition of cell type density between the regions. In addition these 
simulations only incorporated cell types for which there is available experimental data. In 
reality there are multiple cell type regions in the cell all with unique electrophysiological 
properties. The incorporation of fiber orientation was very basic, with the fibers simulated 
in the PM and CT region simulated as lying parallel to one another. In the actual 
myocardium the fibers follow a more free flowing non-descript path. In addition the model 
of the atria is a single cell in depth; in reality the atria had varying depth through its 
structure which may alter the CV of the propagating wave. 
7.4.3 Clinical relevance  
 
This study has identified the role that electrical and spatial heterogeneities play in the 
genesis and prevention of AF. Importantly, this study has identified how the effects of 
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AFER alter the properties of various cells in different ways. For example CT cells seem to 
resist the effects of AFER more effectively than their PM and AT counter parts. These 
differences in behaviour of electrophysiology need to be taken into account when 
developing pharmacological therapies. 
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Chapter 8 
 
Conclusions, discussion, and future Work 
 
This final chapter outlines the major conclusions drawn from the multiple case studies 
performed in this thesis and their relevance to the field of study of AF as a whole. The 
limitations of these studies are discussed along with the possible short and long term 
direction of future work. 
 
8.1 Conclusions 
 
This section reiterates the major conclusions drawn from the multiple case studies 
performed in this thesis. The significance of these conclusions are discussed in relation to 
how they fit into the hypothesis that “AF begets AF”, which is outlined in Figure 8.1. 
Firstly, this includes how AF may be initiated by alterations in the electrophysical 
properties of the cell due to some underlying etiology, such as the KCNQ1 S140G 
mutation, or elevated levels of the Hcy hormone. Secondly, how simulations show that 
AFER increases the tissues susceptibility to the genesis and maintenance of AF. Thirdly, 
that current clinical treatment using drugs such as BB are not substantially effective at 
significantly reducing the occurrence of AF, and finally how theoretical simulations allow 
for conclusions to be drawn about possible future directions of drug developments in 
regards to atrial specific treatments such as the augmentation of ICaL with the 5HT hormone 
or blocking of IKur.  
 
8.1.1 AF genesis in relation to ion-channel remodelling 
 
AF provides a particular problem for clinicians due to its multi-faceted and self 
perpetuating nature. The hypothesis that “AF begets AF”, which is shown in Figure 8.1, 
provides an indication to the overall complexity of the condition. For AF to occur in a 
previously healthy patient there must be an underlying mechanism that allows a 
paroxysmal AF episode to be initiated. The gene mutation KCNQ1 S14G, which is studied 
in detail in Chapter 2, identified how an alteration to repolarisation K
+
 current Iks due to 
said mutation could result in a substrate that could initiate an AF episode (Chen, Xu et al. 
2003). However, while there is a strong link between heart-disease and heredity each 
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individual genetic mutation would require a tailored pharmacological treatment for each 
genetic mutation. Unless a mutation was sufficiently prevalent in the population then 
tailored pharmacological treatments would not be cost effective. In Chapter 3 elevated 
levels of the Hcy hormone altered the electrophysical propertied of several repolarisation 
K
+
 currents (Cai, Gong et al. 2007). Homocystein levels naturally increase with age but 
levels may be reduced by increasing vitamin B levels in the diet (Brattstrom, Israelsson et 
al. 1988). When ionic changes due to the KCNQ1 S140G mutation and elevated levels of 
the Hcy hormone were incorporated into multi scale models to simulate their effects, re-
enrty was observed. While KCNQ1 mutation and Hcy hormone both had differing 
alterations to ion channel properties both studies resulted in shortened APD and ERP 
which increased the tissues susceptibility to the genesis of AF. 
 
In addition to the afore mentioned conditions which increase the susceptibility of the atrial 
tissue to the initiation of AF it has also been observed that rapid pacing of the atrial 
myocardium for prolonged periods results in AFER (Wijffels, Kirchhof et al. 1995).  While 
the exact mechanism by which AFER occurs is not clear, its identification was a major 
advancement in the understanding of the progression of AF from paroxysmal to persistent. 
It was the experimental observation that pacing atrial cells at sufficiently high rates (>600 
bpm) resulted in electrical remodelling of the cells at the ion-channel level. In the short 
term any changes are observed to be protective and reversible. However, under prolonged 
periods of high pacing the effects are seen to be long tern and irreversible (Wijffels, 
Kirchhof et al. 1995). This was first observed in a study on goats wjiffles et. al. and 
subsequently in canine (Yue, Melnyk et al. 1999). Theses studies showed that when atrial 
cells are subjected to a high pacing regime the ICaL current in reduced resulting in a 
shortened APD and ERP. A hypothesis for why such a reduction in the ICaL current occurs 
is that it is a protective mechanism against calcium overload. However, the cost to the cell 
is a reduced ERP which placed the atrial tissue at increased risk of re-entry. If the atrial 
tissue is subjected to high pacing rates for a short periods the reduction in ICaL in observed 
to be reversible. However, experimental data suggests that extended periods at high pacing 
rates the cells are permanently remodelled due to a loss of transcription of the alpha 
subunit which makes up the ICaL pore forming protein (Yue, Melnyk et al. 1999). 
  
In this thesis I have simulated two separate cases AFER based on available experimental 
data provided by Bosch et al and Workman et al in which they studied ionic changes under 
AF patients who suffered AF for 3 and 6 months respectively (Bosch, Zeng et al. 1999; 
Workman, Kane et al. 2001). The studies identified that atrial myocyte isolated from AF 
 158 
patients showed comparable electrophysiological alteration to that observed in sheep. In 
these studies it was concluded that ionic changes particularly the down regulation of ICaL 
and up regulation of IK1 lowered ERP and which favoured the onset of AF, which is 
supported in the simulations in this thesis. 
 
8.1.2 Pharmacological treatment of AF 
 
BBs are typically prescribed as a rate control strategy for the management of AF and are 
routinely prescribed due to their recognised cardio-protective properties (Ishiguro, Ikeda et 
al. 2008).  In Chapter 5, a computational approach was adopted to gain insights into the 
anti- fibrillatory effects of BBs at tissue and organ levels via the incorporation of 
experimental data on the effects of BB into a cell under Control conditions and AFER 
(Workman, Kane et al. 2003). The principal findings were that the application of BB 
moderately prolonged APD and atrial ERP in when applied to both Control cells and those 
which have undergone AFER. It was concluded that BBs have a cardio-protective effect of 
human atrial AP and electrical conduction behaviour, but cannot restore electrical 
properties of AF affected atrial tissue to SR conditions and therefore have limited 
applicability in the diseased stages. 
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Figure 8.1 Schematic showing the mechanisms for AF and targets for possible therapeutic 
treatments. Electrical remodeling (left side) occurs on a time scale of hours to days and structural 
remodeling (right side) occurs over months. The initiation AF due to an ectopic beat results in rapid 
pacing of the atrial cells allowing AFER to occur.  The shortening of APD and atrial ERP increase 
the tissues susceptibility to AF being initiated. Structural remodeling occurs as rapid pacing results 
causing hypertrophy and LA dilation, increasing the myocardial volume and therefore increasing 
the tissues susceptibility to re-entry.  Possible treatments options and are numbered and indicate 
present and future treatment interventions, these include β-Blockers, antiarrhythmic drugs (AADs), 
pulmonary vein isolation, gap junction and sodium channel modulators, maze surgery, anti-
inflammatory drugs (AIDs), rennin-angiontensin-aldosterone system (RAAS). 
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8.1.3 Theoretical treatment of AF  
 
As previously described current pharmacological treatment strategies for the management 
of AF are limited in their effectiveness; therefore the development of new drug therapies is 
vital to improve the prognosis of AF patients (Reiffel 2009). In Chapters 4 and 6 two 
possible treatment options are simulated, the application of the 5HT hormone which is 
observed to increase the current density of ICaL in the atria only, and the blocking of the 
atrial specific repolarisation K
+
 current IKur (Wettwer, Hala et al. 2004; Pau, Workman et 
al. 2007). Investigating and developing these into a possible pharmacological treatment 
strategy in the traditional methods would be an extremely expensive process with no 
guarantee of success (Johnson 2009). However, incorporating the effects of these agents in 
atrial cells into computer models may give an indication of their effectiveness, thereby 
possibly reducing the overall cost of drug development. 
 
The ionic changes due to the 5HT hormone as described by Workman et al. were 
incorporated into an atrial myocyte model under Control and AFER conditions, where 
AFER is simply modeled as a reduction in the ICaL density. Elevated levels of 5HT are 
know to be arrhythmogenic (Dobrev 2007). However, the augmented ICaL current in tissue 
which had undergone AFER resulted in a restored ICaL and therefore provide a cardio 
protective effect. It can be concluded that targeting the 5-HT4 receptors in tissue which has 
undergone AFER may provide a possible target for the development of drug treatments. As 
5HT is used in multiple other processed in the human body there may be significant side 
effects when pursuing such a treatment strategy  
 
Though the reduction of ICaL was sufficient to allow re-entry in the 3D geometry this is not 
an accurate representation of AFER as multiple channels are remodeled which may alter 
the tissues susceptibility to maintain re-enrty significantly (Bosch, Zeng et al. 1999; 
Workman, Kane et al. 2001). It is also noted that in experiments atrial myocytes extracted 
from healthy tissue and subjected to elevated levels of 5HT displayed DAD and EADs 
which are arrhythmogenic in nature. Simulations to test the cells susceptibility to these 
phenomena were performed. In cells which where modeled in accordance with AFER as 
described by Workman et al. DADs and EADs were not observed (Pau, Workman et al. 
2007). However, in cells under Control conditions it was possible to illicit DADs and 
EADs. 
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The blocking of IKur which is simulated in Chapter 6 is of interest when developing a 
treatment for AF as it is atrial specific which would limit any adverse effects on the 
function of the ventricles. Blocking of the IKur channel has been show experimentally and 
with simulations to prolongs APD in cardiac myocytes which have undergone AFER and 
conversely shorten APD and ERP in healthy tissue which may result in increase the tissues 
susceptibility to AF (Kharche, Seemann et al. 2007). Our simulations confirm that the 
blocking of IKur for patients who have undergone electrical remodelling may limit the 
occurrence of AF and aid in rhythm control, although this is not effective once AF has 
been initiated. Current pharmacological agents available to block IKur, such as Vernakalant 
and AZD7009, also block the sodium current (INa) (Persson, Carlsson et al. 2005). Another 
agent, AVE0118, also blocks the transient outward current (Ito) in high concentration and 
are therefore unsuitable to be administered to patients (Gogelein, Brendel et al. 2004). 
However, if an agent was developed which avoided the blocking of these ion channels it 
may be a promising rhythm control treatment for AF.  
 
8.1.4 Role of heterogeneity  
 
The single cell simulations indicate the pro-arrhythmic effects of AFER in AT, CT and PM 
cells are characterized by a shortening of APD, increase in dV/dTmax reduction or ERP, and 
shortening of VW. In addition electrophysiological changes due to varying cell type results 
in a diversion of APDs.  Recent clinical work has identified that structures within the 
atrium are an important consideration when studying the generation and maintenance of 
AF (Wu, Yashima et al. 1998). These structures present them selves as a catalyst for the 
genesis of re-entrant waves due to their differing electrophysiological properties. The 
borders between regions between cell types has been identified as to provide an anchor 
point for spiral rotors (Wieser, Nowak et al. 2008). When performing simulations in the 2D 
atrial sheet the variations in APD between AT, PM and CT cells at the borders provide a 
mechanism by which re entrant waves are initiated. It is observed that these modest 
variations in between cell types aid in the breakup of re-entry waves under SR conditions. 
However, under Bosch and Workman conditions the heterogeneities between cell types in 
increased aiding in maintenance of AF where the CT cells appear to act as an anchor for 
the re-entrant circuit. 
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8.2 Discussion 
 
This discussion section outlines some of the areas which are not included in this thesis but 
are important when considering the topic of AF as a whole. This includes a description in 
to the structural and mechanical aspects of AF and possible alternative treatment targets. A 
discussion into the suitability of cardiac modelling is also included. 
 
8.2.1 Alternative causes and treatments for AF 
 
This thesis has primarily focused on the genesis and maintenance of AF due to changes to 
the electrophysiology of the cardiac myocyte resulting from a range of external factors. 
Investigations into structural and mechanical component in the genesis and maintenance of 
AF are not in the scope of this thesis. However, it is vital area of investigation if the overall 
understanding of AF is to progress. Structural changes include cardiomegaly, which causes 
a stretching of the cardiac wall, increasing its size (Levy, Breithardt et al. 1998). This 
results in an increased area in which re-entrant circuits can occur. In addition fibrosis of the 
cardiac tissue results from ageing or local fibrosis resulting from a myocardial infarction. 
Fibrosis is the process where the fibroblast density is increases impeding electrical wave 
propagation causing a reduced CV. These structural changes also provide the opportunity 
for the development of drug therapies which target the junction gap coupling allowing for 
restoration of CV. In any next generation of models it will be vital to incorporate their 
effects. 
 
 
8.2.2 Can modelling provide the answers? 
 
The traditional techniques to develop treatment for are an expensive and time consuming 
process, in addition there are also many ethical considerations (DiMasi, Hansen et al. 
2003).  In recent years developing new drugs for the treatment of AF had becoming 
increasingly inefficient, with fewer new drugs being approved (Kola and Landis 2004).  As 
computer simulations are relatively cheap to implement when compared to their traditional 
counterparts the development of cardiac modelling to study AF may help improve the 
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efficiency of the development of new pharmacological treatments, therefore modelling 
provides an attractive tool for drug development. 
 
The power of modelling lies in its ability to predict the out come of how alterations to the 
electrophysiology of a cell are manifested at whole heart level. In the near future modelling 
could provide insight into possible drug therapies direction and in the far future modelling 
may play a role in tailoring treatment to patients in real time at the clinical setting. The 
field of cardiac modelling has advanced substantially over the past 50 years. However, the 
current state of modelling is still in the developmental stage whereby models are developed 
empirically based on available experimental data. These models are then validated by 
altering the parameters of the equations to reproduce observed experimental results. If 
models fail to reproduce experimental data then the models need to be improved. While 
current single cell models accurately reproduce single APs in healthy human tissue they 
sometimes fail to fully reproduce effects of diseases observed in the clinical setting.  This 
was observed to some degree in modelling of the Iks current in Chapter 2. The KCNQ1 
S140G mutation was simulated by adding a voltage dependant leakage current to the 
Hodgkin-Huxley formulation provided in the CRN model. This modification to the model 
may not provide an accurate description of the ion channel mutation. Recent work by 
Abraham et al. has suggested that the replacement of the Iks formulation by a series of 
ODEs representing a markov chain may more accurately represent the complexity of states 
the ion channel may lie in (Abraham, Yang et al.). However, simulation of markov chains 
proves to be a problematic in terms of the computation expense required for them to be 
solved numerically. As the CRN model consists of a series of 24 ODEs incorporating the 
IKs markov chain suggested by Abraham et al. would required an additional of 17 ODEs to 
be solved. While this is feasible to implement simulations at a single cell level for a single 
ion-channel the expansion of this to multi-dimensions and would significantly increase 
computation power required. If all ion channels were modelled using markov chains the 
increase in the complexity of the system would be prohibitive. In addition to the increase in 
number of ODSs to be solved markov chains are problematic to solve numerically due to 
the large range of time scales involved in the ODE system very are extremely stiff and 
require advanced ODE solver methods which further escalated the computation expense 
required. To improve simulation methods employing such techniques are necessary 
therefore more creative computation techniques are required. 
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8.3 Future work 
 
This section will outline the possible extensions of projects in this thesis which include the 
addition of a SA node in to the 3D structure and 2D heterogeneous sheet, improvements to 
anatomical structure. 
 
8.3.1 Simulating SA node activity 
 
In multi-scale simulations performed on the 3D atria and the 2D heterogeneous sheet re-
entry was initiated by a S1-S2 protocol, this allowed for the studies to focus on the tissues 
ability to permit the formation of sustainment of re-entrant waves. However, the presence 
of the continuous depolarisation of the SA node is neglected in these studies. The 
incorporation of a SA node (Chandler, Greener et al. 2009) into the multi-scale simulations 
would improve understanding of the in the interaction between the beats of the SA node 
and any re-entrant waves which are present in the atria. The genesis of AF could also be 
studied in relation to the cardiac tissue being subjected to a high pacing regime. In 
addition, simulations of cardioversion could be implemented on 2D and 3D geometries to 
simulate the effects of various protocols which would aid in the breakup of re-enrty and 
restore normal SR. Future studies may also consider mechanism involving malfunctioning 
of intracellular [Ca
2+
]i handling (Hove-Madsen, Prat-Vidal et al. 2006), spontaneous firing 
at atrial blood vessel ostia, interaction between SAN and atria.  
 
8.3.2 Improving Anatomical Structures  
 
The anatomical 3D structure used in simulations was taken from the human heart project. 
However, the resolution of the image is low and does not include fibre orientation or 
differentiate between differing cell types present in the myocardium, which are know to 
exhibit differing electrophysiology. Therefore obtaining detailed MRI images is vital to 
identify fibre orientations and also identify different regions of atrial cell tissue type. There 
could also be the possibility of subjecting tissue to dissection and imunostaining to help 
identify different regions of tissues. The case studies in this thesis focused on macro re-
entrant waves. However, micro re-entry is also an important factor responsible for AF 
(Markowitz, Nemirovksy et al. 2007) and the inclusion of the electrical and spatial 
heterogeneities in the various tissue sub-types in the atrium will further our understanding 
the genesis of AF, especially the micro-entry due to heterogeneity boundaries 
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